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Introduction:  Obesity is a public health concern in its association with various comorbidities, 
especially cardiovascular disease. Negative structural and functional changes of the left ventricle 
are associated with obesity and research is conflicting as to the effect of diet-induced and diet 
plus exercise-induced weight loss in Class II and III obese adults. Purpose: The purpose of this 
study was to examine effect of diet-induced or diet plus exercise-induced weight loss on cardiac 
structure and function in Class II and III obese women.  Methods: 24 healthy, sedentary, obese 
women (BMI: 35.0 to <45 kg/m2; Age: 45.4 + 6.9yrs.) underwent a 12-week diet and exercise 
intervention: caloric restriction alone (DIET), caloric restriction plus aerobic training 
(DIET+AT), and caloric restriction plus resistance training (DIET+RT).  Subjects reported to 
UPMC Presbyterian Hospital to undergo Cardiac MRI to measure left ventricular mass (LVM), 
myocardial fibrosis (Ve), end diastolic volume (EDV), end systolic volume (ESV), and ejection 
fraction (EF).  Results: 18 out of 24 subjects completed the intervention. 16 out of 24 completed 
12 week Cardiac MRI at UPMC Presbyterian. Body weight significantly decreased across all 
treatment groups (~4.5kg lost, p=0.001). Subjects in the DIET group had significantly greater 
reduction in LVM (-7.2 ± 3.9g) than the DIET+AT (2.3 ± 4.7g) and DIET+RT (-0.2 ± 3.5g) 
groups (p=0.007). Subjects in the DIET+RT group had a significantly higher Ve score at 12 
weeks (27.9 ± 1.5%) than subjects in the DIET+AT (26.5 ± 1.4%) and DIET (24.0 ± 0.8%) 
groups (p=0.010). There were no significant changes in EDV, ESV, or EF at 12 weeks between 
groups (p>0.159). Conclusions: In conclusion, only LVM in the DIET group and Ve in the 
THE EFFECT OF WEIGHT LOSS AND EXERCISE ON CARDIOVASCULAR 
STRUCTURE AND FUNCTION IN CLASS II AND III OBESE WOMEN 
 
Steven D. Verba, PhD 
University of Pittsburgh, 2011
 
 5 
DIET+RT showed statistical changes from baseline. Further investigations into the effect of 
weight loss and exercise on cardiac structure and function in Class II and III obese adults are 
warranted to expand upon the results of this investigation. 
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1.0  INTRODUCTION 
 
1.1 OBESITY PREVALENCE 
Obesity is a growing public health concern in association with increased risk for cardiovascular 
disease1, diabetes2,3, certain cancers4,5,6 and other metabolic disorders7. While the rate of 
overweight and obesity appears to have slowed slightly over the past decade, both are still 
prevalent in the United States8. Greater than 65% of American adults are classified as overweight 
(BMI > 25 kg/m2) and more than 32% of American adults are classified as obese (BMI > 30 
kg/m2)8. Additionally, more than 14% of American adults are classified as Class II Obese (BMI 
34.9 – 39.9kg/m2) and approximately 6% are classified as Class III Obese (BMI > 40kg/m2)8. 
Unfortunately, overweight and obesity are prevalent outside of the United States as well. In 
2003, the World Health Organization estimated that there are more than one billion overweight 
adults and 300 million obese adults globally9. Growing evidence linking the association between 
obesity and the risk for development of multiple metabolic diseases, particularly cardiovascular 
disease (CVD), suggests the need for weight reduction in American adults.  
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1.2 CARDIOVASCULAR DISEASE PREVALENCE 
Cardiovascular disease claims more lives per year than cancer10 and the estimated cost to treat 
CVD per year is over $500 billion10. Obesity is an independent risk factor for cardiovascular 
disease11 in its association with dyslipidemia, hypertension, glucose intolerance, inflammatory 
markers, and increased total blood volume11. Weight gain in adulthood, and even adolescence, 
has a severe impact on CVD risk factors, even in individuals who are normal weight by BMI 
classification12. Moreover, a ten-year follow up of the Nurses’ Health Study and the Health 
Professionals Follow-up Study showed that cardiovascular disease risk increased as both men 
and women gained weight through adulthood compared to normal weight age-matched 
controls13.  
The risk for chronic diseases increases in a curvilinear fashion as BMI increases14. 
Mortality rates also increase in a curvilinear fashion as a BMI of 35kg/m2 represents 
approximately three years of life lost, while a BMI of 40kg/m2 represents approximately six 
years of life lost14. Research has shown that as much as a 20-year reduction in life is associated 
with morbid obesity15.  
Additionally, the location of adipose tissue can have a varying impact on cardiovascular 
disease risk. A stronger correlation to cardiovascular disease is apparent when adipose tissue is 
deposited in the abdomen as opposed to general total body obesity16. It is believed that this is due 
to an increase in visceral fat associated with abdominal adiposity compared to general obesity16.  
Aside from the increased risk in comorbidities associated with obesity, research also 
shows a strong correlation between obesity and structural changes. Specifically, left ventricular 
hypertrophy has been shown to have a strong association with cardiovascular mortality17. Left 
ventricular hypertrophy falls into a disease classification referred to as subclinical cardiovascular 
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disease. This term refers to subclinical conditions, or conditions that do not manifest signs and 
symptoms of cardiovascular disease. The Framingham Heart Study showed that 63% of women 
who died suddenly of cardiovascular disease had no previous signs or symptoms of the disease18, 
exemplifying the need to better detect these abnormalities. While left ventricular hypertrophy 
appears to be rare among normotensive normal weight adults19, it is prevalent in normotensive 
and hypertensive obese adults. Increased adipose tissue results in an increase in total blood 
volume, which in turn creates a greater workload placed on the heart to circulate the added 
volume. As more blood flows through the heart, the walls and musculature of the left ventricle 
adapt by increasing in size. This increase in left ventricle size eventually leads to dysfunction in 
the chamber and subsequent cardiac mortality if adipose tissue continues to accumulate on the 
body. However, a reduction in weight may reverse these negative effects and reduce 
cardiovascular disease risk20. 
1.3 EFFECT OF WEIGHT LOSS ON CARDIOVASCULAR DISEASE RISK 
A weight loss of 5-10% from initial body weight has been shown to decrease health risk21. 
Moreover, the National Institutes of Health recommends a weight loss of 10% initial body 
weight in adults with a BMI of > 25kg/m2 22. Four year results from the Look AHEAD Trial 
showed that with an intensive lifestyle intervention, sustained weight loss and subsequent 
improvements in fitness, glycemic control, and cardiovascular risk factors are seen in individuals 
with type 2 diabetes23. Weight loss had also been shown to decrease arterial pressure24. As little 
as an 8kg weight loss is substantial to produce significant reductions in both systolic and 
diastolic blood pressures in hypertensive individuals24. Additionally, weight loss appears to 
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decrease left ventricular mass via a decrease in chronic volume overload25. This subsequent 
decrease in ventricular mass and volume decreases cardiovascular mortality risk. Studies that 
utilize aerobic and resistance training in the reduction of left ventricular hypertrophy in obese 
adults are rare, however training shows an increase in left ventricle mass in normal weight 
athletes26. While training in addition to caloric restriction may result in no change in left 
ventricular mass in obese adults, the quality of the myocardium may improve, therefore 
decreasing cardiovascular disease risk. 
1.4 EFFECT OF PHYSICAL ACTIVITY AND WEIGHT LOSS ON 
CARDIOVASCULAR DISEASE RISK 
Physical activity has an additive effect to diet on weight loss and therefore has a greater impact 
on cardiovascular disease risk. Physical activity has been shown to further reduce weight by 1 to 
2 kg when added to caloric restricition21. Physical activity also has an effect on cardiovascular 
disease risk independent of body weight and weight loss. Physical activity has been shown to 
reduce resting systolic and diastolic blood pressures as well as insulin resistance and glucose 
tolerance3. Additionally, physical activity has been shown to reduce cardiovascular disease risk 
by approximately 20% in men and women when compared to age-matched sedentary controls. 
This reduction in risk increases to approximately 30% with high-intensity physical activity27. 
Unfortunately, physical inactivity is widespread and has become a prominent cause of 
death in the United States7. Physical inactivity has been shown to worsen chronic diseases, as 
well as increase risk for cardiovascular disease, stroke, type 2 diabetes, and obesity7 in 
apparently healthy adults. While adults are recommended to accumulate 150 minutes of 
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moderate-intensity or 75 minutes of vigorous-intensity physical activity each week to promote 
health21, over one third of the population reported not accumulating the required time28. The 
aforementioned statistics exemplify the need for effective strategies to increase physical activity 
and subsequently decrease body weight to reduce chronic disease risk. Figure 1 helps represent 
the need for such strategies by depicting the two outcomes of overweight and obesity. 
 
Figure 1: Potential Overweight and Obesity Pathways 
1.5 TRAINING METHODS TO IMPROVE WEIGHT LOSS 
Behavioral weight loss interventions are designed to modify an individuals’ eating and physical 
activity habits, specifically by reducing calorie intake and increasing calorie expenditure. These 
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changes, theoretically, should create an energy deficit and subsequent weight loss, therefore 
reducing chronic disease risk. Most notably, aerobic-type activities are prescribed for greatest 
weight loss. Recently, greater attention has been paid to the importance of resistance training in 
maintaining lean body mass and improving cardiovascular disease risk while dieting29-30. 
Additionally, resistance training offers a segue into an aerobic exercise regimen as many obese 
individuals may find it difficult to perform the aerobic activities for the required amount of time. 
Beginning with resistance training allows the individual to increase strength which is crucial for 
performing aerobic exercises. 
 While research is contradictory as to the effect of resistance training on subclinical 
cardiovascular disease, aerobic training appears to have a beneficial effect. Weight loss, 
independent of training status, also appears to have similar benefits. However, few studies have 
examined the role of training and weight loss in obese individuals with respect to subclinical 
cardiovascular disease. It is important to determine if weight loss itself is the primary factor for 
improvements in subclinical cardiovascular disease in obese adults, or if the mode by which 
weight loss occurred, i.e. caloric restriction alone, caloric restriction plus aerobic training, or 
caloric restriction plus resistance training, is more critical. 
1.6 DETECTION OF SUBCLINICAL CARDIOVASCULAR DISEASE 
When a patient enters a physician’s office for cardiovascular risk screening, the most common 
testing that occurs is a family history questionnaire, physical examination, and serum blood 
chemistry analysis. Based on these results, the patient is given a Framingham Risk Score31, 
which expresses the 10-year risk of the patient for cardiac events. Current practice guidelines 
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mandate that only moderate or high risk patients receive further testing and treatment32. 
However, from this test, nearly 85% of individuals will be put into a low risk category32. Many 
of these low risk patients have a varying degree of subclinical cardiovascular disease, meaning 
that most likely their first symptom of cardiovascular disease will be an adverse event. This 
presents the need to better understand, detect, and categorize varying levels of subclinical 
cardiovascular disease before it leads to cardiac death. 
 Historically, left ventricular mass has been analyzed using echocardiography. However, 
this method has a low sensitivity (7%) and unreliable accuracy for the detection of left 
ventricular hypertrophy32-34. Additionally, because echocardiography is only a two-dimensional 
measurement, it must use algorithms to estimate total volume and mass of the heart. These 
algorithms are only validated against a normal heart shape, therefore making them unreliable in 
the estimation of the size of an abnormal heart (i.e. hypertrophy due to chronic volume 
overload).  
 Cardiac magnetic resonance imaging (CMRI) is widely becoming the most reliable 
measure of heart mass and volume. This technique measures the heart by taking individual 
“slices” of the heart and stacking them on each other, creating a three-dimensional image. 
Additionally, it is widely used in longitudinal studies due to its excellent interstudy 
reproducibility35.  
 Therefore, the scope of this study will be to examine the effect of weight loss and either 
aerobic or resistance exercise on subclinical cardiovascular disease in obese adults. 
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1.7 SPECIFIC AIMS 
The specific aims of this study are: 
1.) To compare the changes in body weight between three intervention groups: diet only 
(DIET), diet plus aerobic training (DIET+AT), and diet plus resistance training 
(DIET+RT) during a 12-week training study in Class II and III obese women. 
2.) To compare changes in left ventricle mass between three intervention groups: DIET, 
DIET+AT, and DIET+RT during a 12-week training study in Class II and III obese 
women. 
3.) To compare changes in cardiovascular function (end diastolic volume, end systolic 
volume, ejection fraction, and fibrosis) between the three intervention groups: DIET, 
DIET+AT, and DIET+RT during a 12-week training study in Class II and III obese 
women.  
4.) To compare changes in cardiorespiratory fitness between three intervention groups: 
DIET, DIET+AT, DIET+RT during a 12-week training study in Class II and III obese 
women. 
5.) To compare changes in muscular strength as determined by 1-Repition Maximum 
between three intervention groups: DIET, DIET+AT, and DIET+RT during a 12-week 
training study in Class II and III obese women. 
6.) To compare changes in body composition between three intervention groups: DIET, 
DIET+AT, and DIET+RT during a 12-week training study in Class II and III obese 
women. 
7.) To determine the association between changes in weight, aerobic and muscular fitness, 
and body composition, and left ventricular mass and function between three intervention 
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groups: DIET, DIET+AT, and DIET+RT during a 12-week training study in Class II and 
III obese women. 
1.8 HYPOTHESES 
The specific hypotheses of this study include: 
1.) The DIET+AT group will lose more body weight than the DIET+RT group and the 
DIET+RT group will lose more body weight than the DIET only group. 
2.) The DIET+AT group will have a greater decrease in left ventricular mass than the 
DIET+RT group and the DIET+RT group will have a greater decrease in left ventricle 
mass than the DIET group. 
3.) The DIET+AT group will show a greater improvement in cardiovascular function than 
the DIET+RT group and the DIET+RT group will show a greater improvement in 
cardiovascular function than the DIET group. 
4.) The DIET+AT group will have a greater increase in cardiorespiratory fitness than the 
DIET+RT group and the DIET+RT group will have a greater increase in 
cardiorespiratory fitness than the DIET group. 
5.) The DIET+RT group will have a greater increase in 1RM than the DIET+AT and the 
DIET+AT group will have a greater increase in 1RM than the DIET group. 
6.) The DIET+AT group will have a greater improvement in body composition than the 
DIET+RT group and the DIET+RT group will have a greater improvement in body 
composition than the DIET group. 
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2.0  REVIEW OF LITERATURE 
2.1 INTRODUCTION 
Obesity is a complex chronic disease that encompasses genetic, cultural, physiological, and 
metabolic factors22. Obesity has reached epidemic proportions in men and women and poses a 
significant public health challenge in its association with other chronic diseases. Excess body 
weight is a major contributor to preventable death in the United States and needs to be reduced to 
decrease the prevalence of weight-related comorbidities.  
Behavioral interventions can be implemented for obese individuals to reduce caloric 
intake and increase caloric expenditure, therefore reducing body weight. Adults with the greatest 
amount of excess body weight appear to have the most to gain from these interventions, yet this 
group appears to be targeted the least36. Thus, appropriate and effective interventions that focus 
on adults with the greatest levels of obesity need to be employed to reduce weight and improve 
health. 
2.2 OBESITY PREVALENCE 
The classification of overweight and obesity is often based on body mass index (BMI), 
calculated as weight in kilograms divided by the square height in meters. A BMI of 25.0 to 
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29.9kg/m2 is classified as overweight while a BMI of greater than 30.0kg/m2 is classified as 
obese. More specifically, a BMI of 30.0 to 34.9kg/m2 is classified as Class I Obese, BMI of 35.0 
to 39.9kg/m2 is classified as Class II Obese, and a BMI of greater than 40.0kg/m2 is classified as 
Class III Obese. Based upon estimates from the National Health and Nutrition Examination 
Survey (NHANES), the rate of overweight and obesity has been increasing over the past several 
decades for children, adolescents, and adults of all racial and ethnic groups10. Approximately 
68% and 33% of American adults, 20 years of age or older, are classified as either overweight or 
obese, respectively. Moreover, nearly 15% of American adults are classified as Obese Class II 
and 6% are classified as Obese Class III. The rate of increase in morbid obesity is high, in that 
between the five year span from 2000 to 2005, prevalence rates increased by 50%37. While a 
greater percentage of men are categorized in the overweight and Obese Class I categories, 
women make up a greater percentage of those classified as Obese Class II and III for any age 
group10.  
The rising prevalence of obesity reflects the shift in eating and physical activity behaviors 
of the American population. Low-fat, complex carbohydrate meals have been replaced by high-
fat, high-sugar diets, and a decrease in physically demanding work has led way to less active 
lifestyles. This chronic energy imbalance, i.e. greater calories consumed than burned, has led to a 
marked increase in overweight and obesity.  
 Obesity has been shown to be associated with musculoskeletal difficulties13, sleep 
apnea38, as well as diabetes39, hyperlipidemia40, hypercholesterolemia41, cancer of the breast42 
and colon43, cardiovascular disease44, and increased mortality45. Increased mortality due to 
obesity has been linked to the strong association of excess body weight to cardiovascular disease 
risk46. 
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2.3 CARDIOVASCULAR DISEASE PREVALENCE 
The American Heart Association estimates that more than 81 million American adults have one 
or more types of cardiovascular disease10. Cardiovascular disease encompasses stroke, congenital 
heart disease, coronary artery disease, hypertension, and heart failure. Nearly 35% of all deaths 
in 2006 were attributed to at least one form of cardiovascular disease10.  
The most recent statistics suggest that cardiovascular disease is one of the leading causes 
of preventable death in the United States. Nearly one third of these deaths occurred before the 
person was 75 years of age, which is well below the expected average life span for American 
adults. It is estimated that if all forms of cardiovascular disease would be eliminated, average life 
expectancy would increase by 7 years10. 
2.3.1 The Effect of Obesity on Cardiovascular Disease 
Obesity has been shown to be an independent risk factor for cardiovascular disease and 
contributes to cardiovascular disease risk factors, including: hypertension, dyslipidemia, and 
diabetes1,13,15,24,47. Two-year follow-up data from the Multi-Ethnic Study of Atherosclerosis 
(MESA) shows in 6814 adults free of clinical cardiovascular disease, cardiovascular disease risk 
was increased in all racial/ethnic and sex groups with high body mass index values48.   A higher 
body mass index was associated with a 6-20mmHg higher systolic blood pressure, a 4-14mg/dL 
reduction in HDL cholesterol, and 18-55 mg/dL higher triglyceride levels compared to normal 
weight adults. Furthermore, Wannamethee showed in a 12-year follow-up of 6,916 men, a 
significant weight gain (>10%) from initial body mass index resulted in a significant risk of 
developing type 2 diabetes49, an independent risk factor for cardiovascular disease.  
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Obesity has also been linked to cardiac mortality. In a 14-year follow-up of 5,881 
Framingham Heart Study participants, the risk for heart failure increased by 5% in men and 7% 
in women with every 1 kg/m2 increase in BMI50. This evidence is supported by Alpert et al, who 
showed a significant probability of developing heart failure as duration of morbid obesity 
increased51. 
Increased cardiovascular morbidity and mortality may also be attributed to factors such as 
coronary artery calcification, increased left ventricular mass, and increased carotid intima-media 
thickness. These have been observed in obese men and women in higher prevalence than their 
normal-weight age-matched counterparts48. 
2.3.2 Subclinical Cardiovascular Disease 
Subclinical cardiovascular disease is an umbrella term for conditions of the cardiovascular 
system that do not manifest signs or symptoms. Generally, the first sign or symptom of 
subclinical cardiovascular disease is either a sudden cardiac event or sudden cardiac death. 
Subclinical cardiovascular disease is measured using the following techniques: carotid intima-
media thickness, arterial pulse wave velocity, fibrosis, and left ventricular hypertrophy.  
The National Institutes of Health determined subclinical cardiovascular disease to be of 
significant public health concern for two reasons: 1.) there can be a gradual progression of 
subclinical disease to clinical presentation with symptoms if not treated and 2.) subclinical 
disease is an earlier, more medically treatable state than manifested clinical disease32.  
 26 
2.3.3 The Effect of Obesity on Left Ventricular Hypertrophy 
Left ventricular hypertrophy is an independent risk factor for cardiovascular morbidity and 
mortality26. This condition occurs in response to a chronic volume overload associated with 
obesity. Adipose tissue is a highly metabolic tissue and the body must respond by increasing 
total blood volume and cardiac output. These circulatory changes cause left ventricular 
morphology in the form of cavity dilation, which is then believed to elicit a hypertrophic 
response from the myocardium52. Chronic hypertrophy is dangerous because it increases the risk 
for the development of heart failure and sudden death53.  This is evident in further examination 
of the Framingham Heart Study. Men in that study that had left ventricular hypertrophy as 
detected by electrocardiograph had an 8.1% higher risk of sudden death compared to only a 1.9% 
risk of sudden death in men who did not have left ventricular hypertrophy. Likewise, women 
with left ventricular hypertrophy had a 0.9% risk, compared to a 0.4% risk of sudden death in 
those who did not have left ventricular hypertrophy48. 
2.4 WEIGHT LOSS AND HEALTH RISK 
The literature suggesting the association between obesity and diseases such as cardiovascular 
disease, diabetes, and dyslipidemia is vast. However, there is evidence that suggests weight loss 
may improve the outcomes of, or even eliminate, these diseases54. Even a modest weight loss of 
10% initial body weight has been shown to be sufficient to improve health21.  
In some cases, the reduction of body weight has minor consequences. Weight loss has 
been shown to be linked to a greater risk of gallstone formation, loss of lean body mass, mild 
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liver dysfunction, and other less serious conditions55. However, the benefits of weight loss far 
outweigh the risks, and the adverse effects are not convincing enough to contraindicate weight 
loss55. 
2.4.1 The Effect of Weight Loss on Cardiovascular Disease Risk 
Cardiovascular death rates have been linked to higher body mass index in both men and women. 
The risk of death from cardiovascular disease in severely obese adults (BMI > 35kg/m2) is nearly 
3 times greater compared to normal weight (BMI 18.5 – 24.9kg/m2)56. In general, weight 
reduction reduces blood volume, stroke volume, and cardiac output, along with filling pressures 
in all chambers of the heart11. These factors, in addition to reduction in other cardiovascular 
disease risk factors, contribute to the improvement in cardiovascular morbidity and mortality 
seen with weight loss. 
Modest weight loss of approximately 5-10% initial body weight has been shown to 
improve diabetes outcomes in individuals with diagnosed type 2 diabetes, as well as prevent the 
development of diabetes in high-risk overweight and obese adults57. Insulin resistance associated 
with diabetes has been linked to increased inflammatory markers, especially C-reactive protein, 
which is a predictor of atherosclerosis and cardiac morbidity57. Kelley et al found that after 16 
weeks, obese adults had substantial weight loss (12.7 + 2 kg) following a very intensive weight 
loss regimen. Insulin sensitivity improved rapidly and continued to improve with sustained 
weight loss58.  
In a longer prospective study, Sjostrom et al examined 10-year follow-up rates of 
diabetes and diabetes related factors in 4,047 obese subjects who underwent gastric bypass 
surgery. Weight loss after 10 years decreased by 16.1% in the subjects who underwent gastric 
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bypass surgery compared to a 1.6% increase in the non-treatment control group. Ten-year 
recovery and incidence rates were markedly lower in the surgery treatment group compared to 
controls, suggesting a decrease in diabetes risk with long term weight loss59. 
 Abnormally high levels of blood lipids classify another risk factor to 
cardiovascular disease. Weight loss has been shown to reduce LDL-C and triglyceride blood 
levels, and HDL-C concentrations are typically increased when weight loss is sustained57. 
Wadden et al conducted a prospective evaluation of 25 obese women over a 100-week period. At 
100 weeks follow-up those women who lost >10% initial body weight had significantly greater 
reductions in total LDL-C and triglyceride levels compared to women who had only lost 5-10% 
of initial body weight. Furthermore, subjects who regained weight during the final 50 weeks of 
observation experienced significant increases in LDL-C levels (p=0.05)60. This suggests that at 
least 5% weight loss is necessary for beneficial reductions in total blood lipids, and these values 
can revert to baseline with weight regain. 
An additional contributor to cardiovascular disease is hypertension. Weight loss is shown 
to reduce blood pressure, and does so in a dose-response manner55. Some studies suggest that 
clinically meaningful reductions in both systolic and diastolic blood pressure can occur before an 
overweight or obese person reaches ideal body weight61,62. Much like with diabetes, weight loss 
can prevent the onset of hypertension in overweight and obese men and women. A prospective 
study by Huang et al demonstrated that long-term weight loss after 18 years of age was related to 
a significantly lower risk for hypertension. Furthermore, weight regain significantly increased 
the risk for the development of hypertension. Relative risk for 5.0-9.9kg lost was 0.85 and 0.74 
for a loss of greater than 10kg compared to less than 2kg weight loss. Conversely, for a gain of 
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5.0-9.9kg, relative risk was 1.74 and significantly higher (5.21) for a weight gain of greater than 
25.0kg63.  
2.4.2 The Effect of Weight Loss on Left Ventricular Hypertrophy 
Hypertrophy and remodeling of the left ventricle due to chronic obesity are associated with 
increased risk for morbidity and mortality17. Thus, it is important to implement successful 
weight-loss strategies to reduce left ventricular hypertrophy and improve cardiovascular disease 
risk.  
In a 6-month study of 82 overweight and obese adults, Hinderliter et al found that 
participants in diet only and diet plus physical activity groups lost significant weight from 
baseline (7.4 and 2.3kg, respectively). Concomitant with these decreases in weight were 
reductions in left ventricular relative wall thickness (p=0.003), posterior wall thickness (p=0.05), 
and septal thickness (p=0.004), with a trend in reduction of left ventricular mass (p=0.08) 
compared to the control group64. 
These results are confirmed by more recent studies of Rider65 and de las Fuentas66, who 
showed that significant weight loss over a 1 or 2 year period results in beneficial changes in left 
ventricular mass and function in obese men and women. 
2.5 PHYSICAL ACTIVITY AND WEIGHT LOSS 
Physical activity is shown to be beneficial in reducing body weight, as well as preventing weight 
gain and weight regain67. Regular physical activity is recommended by all public health agencies 
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as a critical component of weight loss. Moderate intensity physical activity between 150 – 250 
minutes per week is effective in preventing weight gain. However, this amount of physical 
activity will only produce modest weight loss without sufficient caloric restriction. Greater 
amounts of physical activity, at least 250 minutes per week, are needed to produce significantly 
meaningful weight loss. Moreover, long term weight loss may require up to at least 300 minutes 
per week of moderate intensity physical activity68.  
2.5.1 The Effect of Aerobic Training on Weight Loss 
Studies that examine sedentary overweight and obese adults with physical activity as the only 
intervention generally result in 3 – 5% reduction from baseline weight. As aforementioned, 
significantly greater weight loss may require higher levels of physical activity. Unfortunately, 
most individuals may find this amount of physical activity off-putting or difficult to attain. 
Nonetheless, studies that examine a dose of physical activity no greater than 150 minutes per 
week show no significant reduction in baseline body weight. 
Gwinup et al found that obese women who walked for no more than 30 minutes per day 
did not see any significant reduction in baseline weight. Additionally, it was not until the women 
approached or exceeded 30 minutes per day that weight loss was significant. Weight loss 
generally paralleled time spent walking when the amount exceeded 30 minutes per day69. 
A more recent study by Jeffery et al showed that obese men and women who walked for 
> 75 minutes per day had significantly greater weight loss at 12 months (8.5 + 7.9kg) and 18 
months (6.7 + 8.1kg) than did those in a standard obesity treatment group (6.1 + 8.8, 4.1 + 7.3kg, 
respectively)70. 
 31 
Even more recent, Christiansen et al examined the effect of exercise and diet-induced 
weight loss on 79 obese adults over a 12-week intervention. Subjects in the exercise only group 
participated in three 60 – 75 minute training sessions per week. Subjects in this group reported 
an average of 3.5 kg weight loss at the end of the 12-week intervention. 
2.5.2 The Effect of Resistance Training on Weight Loss 
Resistance training is becoming an integral component of exercise prescriptions that 
target weight reduction. Resistance training is recognized by the American College of Sports 
Medicine as critical in maintaining health, and it is recommended to perform resistance exercises 
at least twice weekly68.  
Current research has shown that resistance training reduces fat mass and increases lean 
body mass. This relationship, however, results in little to no weight loss71-74. The premise behind 
performing resistance training is that regular (2 to 3 times per week) resistance training is 
associated with at least a 1 to 2 kg increase in lean body mass. This increase in lean body mass 
will, in turn, increase resting metabolic rate and increase daily energy expenditure over time71.  
To further examine the effect of resistance training on weight loss, Kraemer et al75 found 
that after a 12 week intervention involving diet only, diet plus aerobic training, or diet plus 
aerobic and resistance training, there was no significant difference in weight loss between the 
three groups. Participants in the group that received resistance training had a higher percentage 
of their total body weight loss represented by fat mass. 
Similarly, Rice et al76 found that during a 16-week intervention including obese men, 
reductions in weight and adipose tissue where not significantly different between those who 
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received a hypocaloric diet or hypocaloric diet with either resistance or aerobic training. Lean 
body mass was only preserved with resistance training at the end of the 16 week period. 
Given the association of visceral fat depots to cardiovascular disease, of potentially 
greater importance is the effect of resistance training on visceral adipose tissue. Sixteen weeks of 
resistance training alone showed significant reductions in visceral fat74. In addition, Ross et al 
demonstrated significant reduction in visceral fat between obese men randomized into diet alone, 
diet plus aerobic training, or diet plus resistance training. However, there was no significant 
difference between the groups, but visceral fat mass was decreased greater than total body 
subcutaneous fat mass in the training groups77. 
 These findings suggest that the effect of resistance training on weight loss may 
not be any greater than the effect of aerobic training. However, resistance training appears to 
preserve lean body mass in the presence of calorie restriction, therefore improving the metabolic 
profile of the individual30. 
2.6 PHYSICAL ACTIVITY AND CARDIOVASCULAR DISEASE 
Both aerobic and resistance training have been shown to be beneficial when added to caloric 
restriction on reducing body weight. Regular physical activity is recommended by the American 
College of Sports Medicine68 to improve health outcomes as well, independent of weight change. 
All healthy adults ages 18-65 years are recommended to attain at least 30 minutes of moderate-
intensity physical activity at least 5 days per week or vigorous-intensity physical activity at least 
20 minutes 3 days per week. Additionally, 8 – 10 muscle strengthening activities should be 
performed at least 2 days per week to maintain good health and physical independence78. 
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Furthermore, activity exceeding the recommended amount will result in greater improvements in 
health. 
Counterproductive to an increase in physical activity is an increase in sedentary 
behaviors. Physical inactivity has become widespread in the United States and contributes to 
cardiovascular disease, congestive heart failure, stroke, type 2 diabetes, and other chronic 
diseases7. Men who spend more than 10 hours per week in a car or more than 23 hours per week 
in other combined sedentary behaviors are at least 80% more likely to die from cardiovascular 
disease than those who spend less than 4-10 hours, respectively7. Thus, public health promotion 
efforts need to target sedentary behaviors and emphasize the benefits of increased physical 
activity for cardiovascular disease risk. 
2.6.1 The Independent Effect of Aerobic Training on Cardiovascular Disease 
There is a growing body of literature that supports a reduced risk of cardiovascular disease with 
increased levels of physical activity and cardiorespiratory fitness. Regular physical activity is 
especially important in individuals with insulin-resistant conditions such as type 2 diabetes and 
obesity79.   Regular physical activity also reduces stress and anxiety, which are possible 
correlates to future cardiovascular events80. Additionally, there is a dose-response relationship to 
the amount of physical activity performed and risk for cardiovascular disease27.  
Haapanen et al examined 1,072 men ages 35-63 years. Men who accumulated moderate 
intensity physical activity showed a significant reduction in cardiovascular disease risk compared 
to those who only did light activity. Even as little as one or more hour per week of gardening was 
associated with a reduction in cardiovascular disease mortality81. 
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Further examination of 6,131 men and women in the Alameda County Study82 showed 
that physical activity was inversely related to cardiovascular disease risk in both men and 
women. Long walks and swimming were associated with at least a 50% reduction in 
cardiovascular disease mortality compared to those who did not participate in long walks or 
swimming. 
One of the largest prospective studies to examine women, the Nurses Health Study, 
followed 72,488 women ages 40 to 65 years. Brisk walking of 3 hours or more per week resulted 
in a relative risk of cardiovascular disease mortality of 0.65 compared to not walking. The 
association was similar in those women who participated in vigorous walking 3 hours or more 
per week compared to women who did not walk83. 
2.6.2 The Independent Effect of Resistance Training on Cardiovascular Disease 
A reduction in skeletal muscle mass secondary to aging or reduced physical activity contributes 
to an increase in cardiovascular disease risk factors30. The role of resistance training on 
cardiovascular disease risk factors in obese adults is vague; however, the cardiovascular 
adaptations to resistance training in normal weight athletes and leisurely-active adults have been 
well-documented18,29,84,85. 
In adults free of underlying cardiovascular disease, the greatest improvements in health 
from resistance training tend to be a result of an improved metabolic profile from an increase in 
skeletal muscle mass30. Additionally, these improvements have been shown without an increase 
in cardiovascular fitness or body fat percentage86. 
 The effects of resistance training on blood pressure are not as well documented as 
with aerobic training, but the current literature suggests that it is beneficial. Cornelissen and 
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Fagard conducted a meta-analysis87 of 9 randomized controlled trials where resistance training 
was the only form of treatment. Their results show that resistance training can reduce systolic 
blood pressure by 3.2mmHg and diastolic blood pressure by 3.5mmHg. These results suggest 
that moderate intensity resistance training is not contraindicated for adults with high-normal 
blood pressure. 
These results seem modest, but a reduction of only 3mmHg in systolic blood pressure has 
been shown to reduce cardiac morbidity by nearly 10%, stroke by nearly 15%, and all cause 
mortality by nearly 5%88. 
 Even when the outcome is not weight loss, aerobic and resistance training have 
beneficial effects on the cardiovascular system. While many adults participate in behavioral 
interventions to reduce body weight, an increase in physical activity achieved through these 
programs has beneficial effects on health. These programs should focus on the weight-loss 
effects of physical activity, as well as the cardiovascular benefit achieved independent of weight 
loss. 
2.7 IMAGING TECHNIQUES TO DETECT CARDIOVASCULAR DISEASE 
The detection of subclinical cardiovascular disease has previously been through use of two-
dimensional echocardiography. However, given that hypertrophy is an abnormal state of the 
heart, echocardiography produces widely variable and inaccurate measurement of the left 
ventricle32-34. This error is the result of a general formula used to estimate a three-dimensional 
shape of the heart from the two-dimensional image. This technique is accurate when measuring a 
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normal heart; however the increased myocardium of the left ventricle is not accounted for in the 
formula. 
 A more accurate measure, cardiac magnetic resonance imaging (CMRI), has been 
adopted as the primary measuring tool in large epidemiological studies32. CMRI obtains multiple 
images of the heart measured at 1-cm intervals from the mitral valve plane to the heart apex32. 
These images are able to depict the inner and outer border of the myocardial wall, thus providing 
an accurate measure of ventricular volume. Volume is then multiplied by myocardial density 
(1.05g/cm3) to obtain mass. This method allows for any abnormalities in left ventricular shape to 
be accounted for in the images. CMRI has a much smaller error rate (5%) than 
electrocardiography (20%)32 and has been determined to be the most accurate and reliable 
measure of left ventricular mass and volume35. 
2.8 SUMMARY 
Obesity has reached epidemic proportions and is a serious public health concern. Obesity is 
directly related to cardiovascular disease risk. Reducing body weight through diet and exercise 
can improve cardiovascular-related outcomes associated with obesity. Regular aerobic and 
resistance training has beneficial independent effects on cardiovascular health, as well.  
Class II and III obese adults are at greater risk for cardiovascular disease and other 
comorbidities, yet this population has not been studied in great detail39. While these individuals 
would benefit greatly from a clinical weight loss and behavioral modification intervention, this 
literature is currently lacking outside of the realm of bariatric surgery36. Training studies 
including aerobic training are even more rare, with resistance training in this population being 
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completely absent from the literature. This suggests a need to explore the effect of weight loss 
and different training modalities on cardiovascular morphology in Class II and III obese adults.   
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3.0  METHODOLOGY 
3.1 SUBJECTS 
A total of 33 women between the ages 30 – 55 years were recruited to participate in this study. 
Subjects were required to be apparently healthy, yet sedentary and obese according to BMI 
stratification ( > 35.0 kg/m2 - < 45.0 kg/m2). While morbid obesity has been shown to be 
associated with a greater number of comorbidities22, little research has been conducted to 
determine the association between the effect of weight loss and exercise training on cardiac 
structure and function in Class II and Class III obese adults. Individuals at low or moderate risk 
according to ACSM guidelines were recruited while those individuals at high risk were excluded 
from this study. Individuals with conditions that have negative influences on weight loss were 
also excluded. Additionally, individuals meeting the following conditions were excluded: 
1. Currently pregnant, pregnant in the past 6 months, or planning on becoming pregnant in 
the next 6 months. Women who are currently pregnant have different nutritional needs 
and potentially have limitations to physical activity than non-pregnant women. Moreover, 
vigorous exercise is not recommended for women who are pregnant, which would limit 
the ability of these women to participate in the graded exercise test in this study. 
Pregnancy is also a contraindication for performing a DXA analysis of body composition. 
Women who have been pregnant within the past 6 months or who are breast feeding may 
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not be weight stable, which would potentially confound the influence of the proposed 
interventions on changes in body weight and body composition in this study. 
2. Regularly exercising for greater than 60 minutes per week. An important component of 
the design of this study is to examine the effect of either aerobic or resistance exercise to 
an energy restricted diet. Therefore, to minimize the potential of a confounding effect, it 
is important to include only sedentary individuals in this study, which will also allow for 
maximal effects of the prescribed exercise on outcome measures.  
3. Taking prescription or over-the-counter medications that affect body weight, metabolism, 
blood pressure, or heart rate. This study will examine the effect of a behavioral lifestyle 
intervention on weight loss, with the intervention including changes in physical activity 
and/or dietary behaviors. Therefore, medications that affect body weight could confound 
the results of this study, and are excluded. 
4. Having physical limitations that hinder or prevent exercise. The ability to perform 
physical activity is imperative in the two intervention arms including aerobic or 
resistance exercise. Physical limitations could prevent exercise, thus not fully measuring 
the added effect of exercise to diet in weight loss.  
5. Currently being treated for coronary heart disease, diabetes mellitus, hypertension, or 
cancer. Individuals with these conditions may require additional medical clearance and 
supervision that is outside the proposed scope of this study, or may require alterations in 
the intervention that would limit their ability to comply to the standardized intervention 
that is proposed. 
6. Having a resting systolic blood pressure of > 150mmHg of diastolic blood pressure of > 
100mmHg or currently taking any medications that affect blood pressure or heart rate 
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(i.e. beta blockers). Hypertension at these levels may contraindicate participation in the 
exercise prescribed as part of the interventions in this study. Moreover, cardiorespiratory 
fitness in this study is being assessed using a submaximal exercise test to 85% of age-
predicted maximal heart rate that is not supervised by a physician. Therefore, blood 
pressure at these levels may pose a safety concern in this study. Additionally, if taking 
medications that affect the heart rate response to exercise, the termination heart rate 
during the graded exercise test will not be able to be determined. 
7. Currently enrolled in an exercise or weight control study or participating in an exercise or 
weight control study in the past 6 months. Enrollment in an outside weight loss study, or 
recent participation in a weight loss study may confound the weight loss interventions 
proposed for this study. 
8. Have lost and not regained > 5% body weight in the past 6 months. This may confound 
the effects of the intervention on weight loss, body composition, and other outcomes 
measured in this study. Moreover, based on our experience, the intervention may shift to 
a focus on prevention of weight regain rather than continued weight loss in these 
individuals. 
9. Currently being treated for any psychological problems or taking any psychotropic 
medications. Receiving an intervention for psychological issues may confound the effect 
or may affect compliance to the intervention proposed for this study. Moreover, many 
psychotropic medications can affect body weight, and therefore should be excluded form 
this study. 
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3.2 RECRUITMENT AND SCREENING 
Subjects were recruited through several media outlets in the Greater Pittsburgh Area that 
included: television and Craigslist advertisements as well as local flier postings. Additionally, 
letters were mailed to individuals registered in the Obesity and Nutrition Research Center 
(ONRC) database. The University of Pittsburgh Institutional Review Board (IRB) approved all 
recruitment methods and materials. Interested individuals were provided with the telephone 
number of the University of Pittsburgh Physical Activity and Weight Management Research 
Center. Upon calling, individuals talked to trained staff and masters and doctoral level graduate 
students to receive further information of the methodology of the study. This initial screening 
included a brief description of the study and upon further interest by the individual, questions 
regarding demographic background, physical health, and medical history determined eligibility.  
Upon successful completion of the phone screening, eligible participants were invited to 
attend an orientation session where complete details of the study were given by the Principal 
Investigators (PIs) and Director of the Physical Activity and Weight Management Research 
Center. Individuals attending the orientation were encouraged to engage in a “question-and-
answer” session following the overview. Additional orientation sessions were scheduled to 
accommodate the needs of all eligible participants. Committed participants completed informed 
consent documents to participate and were asked to complete a Physical Activity Readiness 
Questionnaire (PAR-Q)89 to detect those at high risk for participating in regular exercise. Finally, 
individuals were required to obtain physician’s written consent to ensure safety during this 
weight loss and exercise intervention. 
Eligible participants with signed informed consent, physician clearance, and who were 
determined to be low risk for exercise underwent baseline assessments. Assessments included 
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measurements of: height, weight, body composition, cardiorespiratory fitness, muscular strength, 
cardiac structure and function, physical activity, and dietary intake. Assessment procedures are 
described in Section 3.3 below. Participants who completed baseline assessments were 
randomized to one of three intervention groups (see Figure 2 below). The University of 
Pittsburgh Institutional Review Board approved all study procedures.  
 
Figure 2: Study Progression 
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3.3 ASSESSMENT PROCEDURES 
Assessments occurred at 0 (baseline) and 12 (final) weeks at the University of Pittsburgh 
Physical Activity and Weight Management Research Center. Assessments were conducted 
between 7:30 and 10:30am Monday through Friday and required approximately 90 to 120 
minutes to complete. The assessments included measurements of:  height, weight, body mass 
index, anthropometric measurements, body composition, cardiorespiratory fitness, muscular 
strength, cardiac structure and function, physical activity, and dietary intake. Subjects were 
required to report to the University of Pittsburgh Medical Center Presbyterian Hospital at an 
additional appointment time for cardiac magnetic resonance imaging to measure cardiac 
structure and function. 
3.3.1 Height, Body Weight, and Body Mass Index 
Height was measured to the nearest 0.01cm at the baseline assessment only using a wall-
mounted stadiometer (Perspective Enterprises; Portage, MI). Participants had height measured 
with shoes removed. Body weight was measured to the nearest 0.1kg on a Tanita WB-110A 
digital scale (Tanita Corporation; Arlington Heights, Il) at 0 and 12 weeks with shoes removed 
and in a lightweight hospital gown. Body mass index was calculated as body weight in kilograms 
divided by square height in meters (kg/m2).  
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3.3.2 Body Composition 
Body composition was assessed using a GE Lunar Prodigy dual-energy x-ray absorptiometer 
(DXA) (GE Healthcare; Madison, WI). Calibration and scanning speed was performed prior to 
testing per manufacturer guidelines. Subjects were asked to remove any jewelry or metal items 
and be robed in the lightweight hospital gown. Subjects were required to undergo a pregnancy 
test prior to having the DXA scan completed. The low level radiation that is present with the 
scan can potentially harm the fetus. Participants were asked to lay motionless on the DXA bed 
for 10-15 minutes while the machine scanned total body mass. Measurements that were attained 
included: percent body fat, total fat mass, total lean mass, and bone mineral density. An 
individual-specific printout was attained for each subject and included in that subjects’ 
assessment data folder. A trained professional conducted each DXA scan.  
3.3.3 Anthropometric Measurements 
Elevated adipose tissue, especially in the abdominal region, has been linked to increased risk for 
cardiovascular disease90. Abdominal adiposity was measured by waist circumference and waist-
to-hip ratio. Measurements were taken at 0 and 12 weeks with subjects dressed in the lightweight 
hospital gown. Waist and hip circumferences were measured to the nearest 0.1cm using a Gulick 
tape measure. Waist circumference was measured horizontally at the iliac crest. Hip 
circumference was taken at the largest circumference horizontally at the buttocks. Two 
measurements were taken at each site, and a third was taken if the first two measurements 
differed by more than 2.0cm. The mean of the two closest measurements was recorded for data 
collection.  
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Resting heart rate was measured at the radial artery for 30 seconds following a five-
minute resting period during which the participant sat quietly in the upright position with feet flat 
on the floor.  Resting blood pressure was taken immediately after the resting heart rate 
measurement and was performed using a standard vertical mercury sphygmomanometer with the 
stethoscope placed on the antecubital space on the left arm of the participant. Two blood pressure 
measures were taken with a one-minute waiting period between each measurement. A third 
blood pressure was taken if the difference between the systolic blood pressure was > 10mmHg or 
if diastolic blood pressure was > 6mmHg. If the resting systolic blood pressure was > 150mmHg 
or diastolic blood pressure was > 100mmHg the subject was excluded. 
3.3.4 Cardiorespiratory Fitness 
Cardiorespiratory fitness was assessed via a submaximal graded exercise test utilizing a modified 
Balke protocol at 0 and 12 weeks. All graded exercise tests were performed at the Physical 
Activity and Weight Management Research Center and were conducted by a certified Exercise 
Specialist as recognized by the American College of Sports Medicine. The metabolic cart 
(SensorMedics Vmax Metabolic Measuring Cart; SensorMedics; Yorba Linda, CA) was 
calibrated for air volume and gas analysis prior to each test.  
The following protocol was administered for each graded exercise test: Subjects entered 
the testing room and were given a brief overview of the test. The subject was then familiarized 
with the Borg 15-point Rating of Perceived Exertion (RPE) Scale91. The subject was prepared by 
cleaning each site with rubbing alcohol where the 12-lead electrocardiograph (EKG) leads were 
to be placed. The subject was then fully hooked up to the EKG and be fitted to the airflow 
mouthpiece and head support system. The speed of the treadmill was set at 80.4 m/min (3.0mph) 
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and remained constant throughout the test. The grade of the treadmill started at 0% and increased 
by 2.5% every 3 minutes. Heart rate and 12-lead EKG were monitored continuously throughout 
the test. Blood pressure and ratings of perceived exertion were obtained at the end of each stage 
and at test termination. Expired gas volumes and concentrations were measured continuously 
throughout the duration of the test using the metabolic cart. Termination of the test occured at 
85% of the subjects’ age-predicted maximal heart rate as determined by the equation 220-age. 
Criteria for termination included subject report of any of the signs or symptoms that are 
indicative of test termination as described by the American College of Sports Medicine. Upon 
attaining 85% maximal heart rate, subjects performed a three minute active recovery period at 
0% grade and a speed between 2.0 – 2.5 mph with the gas analyzing mouthpiece and headgear 
removed. A recovery blood pressure was taken and the subject sat on the hospital bed for three 
minutes to allow heart rate and blood pressure responses to return toward resting values. All 
EKG printouts were sent to a board certified cardiologist to ensure no contraindications to 
participating in exercise. All testing staff and personnel were certified in cardiopulmonary 
resuscitation (CPR) and use of the Automated External Defibrillator (AED), with safety 
equipment readily accessible in the testing room.  
3.3.5 Muscular Strength 
Muscular strength was assessed at baseline and 12 weeks utilizing the chest press, seated row, 
and leg press. These muscle groups were tested as they represented the largest muscle groups 
that were exercised throughout the course of the intervention. Additionally, these measures 
allowed for the assessment of strength gains in both upper and lower body musculature. All 
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resistance training assessments were conducted on plate-loaded machines to ensure proper safety 
of the participant while performing each exercise. 
The chest press and seated row were conducted to assess one of two separate upper body 
strength gains. The subject started by sitting on the Precor™ vertical chest press machine. The 
seat was adjusted for participant height so that the handles of the machine were at mid-chest 
level and the feet flat on the floor.  The hands were placed on the machine handles at either a 
prone or neutral grip, dependant upon participant preference. The subject warmed up with a set 
of 5 repetitions with 25 pounds loaded on the weight stack.  Once the warm-up phase was 
completed, a rating of perceived exertion (RPE) was attained using the 10-point OMNI RPE 
scale. If the RPE was less than 5, the weight increased by 10 pounds. No further warm-up was 
performed if the RPE was greater than 7. The assessment trial began after a 30 second rest 
period. At that point, single-repetition effort was performed with the resistance progressively 
increased by 1-20 lbs until the subject could no longer complete the selected repetitions.  The 
goal was to determine 1-Repetition Maximum within 4-6 trials, with rest periods of 60 seconds 
minute between trials.  All repetitions of the assessment were performed at the same speed and 
range of motion remained consistent throughout the trial.  The final weight successfully lifted 
was recorded as the absolute 1-Repetition Maximum). This same protocol was then repeated for 
the seated row to attain a second measure of upper body strength. For this assessment, the subject 
sat on the Precor™ seated row machine with the seat positioned so that feet were flat on the floor 
and hands at a neutral grip. The final weight successfully lifted was recorded as the absolute 1-
Repetition Maximum for this exercise. 
The leg press was the final measure of muscular strength gains as it represented lower 
body strength. The participant sat on the Precor™ leg extension apparatus with knees resting in a 
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flexed position over the leg pad. Assessment staff assisted the subject in placing the seat of the 
apparatus at a setting that allowed the knee to maintain a 90-degree angle of flexion.  The subject 
warmed up and 1-Repetition Maximum was determined following protocol aforementioned for 
upper body strength measurements. 
The final weight obtained through 1-Repetition Maximum testing during baseline 
assessments was used to develop a strength training protocol for each participant ensuring that 
each person was trained to her individual ability. 
3.3.6 Cardiac Structure and Function 
Subjects underwent an imaging technique to assess changes in left ventricular mass, fibrosis, end 
diastolic volume, end systolic volume, and ejection fraction at 0 and 12 weeks. Scans were 
conducted and read by a cardiologist blinded to treatment group assignment. Left ventricular 
mass and end diastolic volume were determined by steady state free precession cine pulse 
sequences, which yield high temporal resolution (30 frames per cardiac cycle) and high spatial 
resolution (typical acquisition parameters: 1.6 x 2.3 mm in plane spatial resolution, 6 mm thick 
slices, 4 mm gap, flip angle 50 degrees, 1100 Hz/pixel; TR 3.0 msec; TE 1.2 msec FOV 40x 36 
cm; matrix 256 x160; GRAPPA acceleration factor 2; retrospective ECG gating to capture the 
entire cardiac cycle). To compute left ventricular mass, the volume of myocardium enclosed by 
tracing all of the endocardial and epicardial borders at end diastole were multiplied by the 
thickness of the slice plus the interslice gap and myocardial density (1.04 g/mL). The blood pool 
volume enclosed by endocardial borders yielded left ventricular end diastolic volume. Papillary 
muscle mass was included in the left ventricular volumetric measure and excluded from left 
ventricular mass measures. Measurements were assisted by semi-automated algorithms on 
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workstations (2 Siemens Leonardo workstations with Argus software; 1 Vital Images 
workstation and 4 PCs with Medis QFLOW and QMASS software). 
  Prior to the scan, the participant registered and was directed to the Cardiovascular 
Institute. The participant then changed into a hospital gown with only clothing above the waist 
removed. Any metallic objects (e.g. watch, glasses, jewelry, ear rings, etc.) were removed and 
placed in a secure locker. The participant then received an IV line for the contrast dye and blood 
sampling. The participant then lied in the supine position on the scanner table with four ECG 
electrodes attached. She was given head phones with disposable ear covers to allow 
communication with the technologist. A squeeze ball alarm was placed in the participant’s hand 
to alert the technologist immediately of an emergency. Anterior cardiac chest coils were then 
placed on the participant's chest. These are the antennae that permit signal capture to generate the 
required images. The table and participant were moved to the center of the short/wide bore 
magnet (Siemens Espree model) and scanning commenced for pre-contrast sequences. The 
technologist then entered the suite to hand inject the gadolinium contrast (Prohance 0.1-0.2 
mmol/kg contrast dose) and observed for any adverse reactions. The participant was then 
removed in the same fashion as the beginning of the scan (but in reverse order) after images were 
successfully acquired. 
3.3.7 Physical Activity 
Physical activity was assessed at baseline and 12 weeks using the Paffenbarger Physical Activity 
Questionnaire92. This particular questionnaire estimates the average number of flights of stairs 
and city blocks walked each day for the sole purpose of exercise. Additional information 
regarding any sport, recreation, or fitness activities that the subject participated in over the 
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previous week was documented. If any illness, family circumstance, or vacation made the 
previous week out of the ordinary, the subject recalled the last normal week. Results were 
converted to kilocalories per week. A trained staff member or graduate student from the Physical 
Activity and Weight Management Research Center administered this questionnaire.  
3.3.8 Dietary Intake and Eating Behaviors 
Dietary intake was assessed using the Block Food Frequency Questionnaire (FFQ) (Block, 
2005.1). This questionnaire measures how often in the past year a person consumes a certain 
food, ranging from “Never” to “Every Day”. Additionally, portion sizes are also determined, 
ranging from “1/4 cup” to “2 cups”. This questionnaire has been previously validated in 
estimating daily caloric intake93. Dietary intake was measured at 0 and 12 weeks. 
 Eating behaviors were assessed using the Eating Behavior Inventory (EBI)94. This 
questionnaire includes a 26-point checklist regarding eating and shopping habits. Responses can 
range from “Never of Hardly Ever” to “Always or Almost Always”. This questionnaire has been 
previously validated94.  
3.4 EXPERIMENTAL DESIGN 
This study was a 12-week randomized controlled trial (RCT) to examine the effect of weight loss 
with and without either aerobic or resistance training on cardiac structure and function in Class II 
and III obese adults. This intervention was conducted at the University of Pittsburgh Physical 
Activity and Weight Management Research Center. Upon successful completion of baseline 
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assessments and physician clearance, subjects were randomly assigned into one of three groups: 
1.) standard behavioral weight loss: diet only (DIET), 2.) diet plus aerobic training (DIET+AT), 
and 3.) diet plus resistance training (DIET+RT). Each group and its corresponding intervention 
will be provided in further detail below. The study timeline is illustrated in Figure 3. 
 
Figure 3: Study Timeline 
3.5 STANDARD BEHAVIORAL WEIGHT LOSS INTERVENTION: DIET ONLY 
The diet only intervention arm (DIET) was conducted at the University of Pittsburgh Physical 
Activity and Weight Management Research Center. This intervention included a 12-week 
behavioral education program in which participants attended weekly group sessions. Group 
sessions lasted approximately 30 – 45 minutes and were conducted by graduate students 
educated in nutrition, exercise physiology, and behavior modification. Group sessions focused on 
approaches that change eating behaviors based on the Social Cognitive95 and Problem Solving96 
Theories. 
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Subjects were weighed prior to each group session. These weekly values allowed the 
interventionists, as well as subjects, to monitor weight changes over the course of the 
intervention. If a participant missed a group session, that participant was required to make-up 
that session with one of the interventionists before the next meeting. In the case of vacation or 
extended absence, appropriate materials were provided for the participant. The timeline for group 
sessions is outlined in Table 1. 
Table 1: Session Type by Intervention Week 
Session Intervention Week 
 1 2 3 4 5 6 7 8 9 10 11 12 
Group 
Session 
(Individual 
Sessions as 
Necessary) 
× × × × × × × × × × × × 
 
3.5.1 Dietary Component 
Participants were given a calorie and fat gram goal at the beginning of the intervention according 
to their initial body weight (Table 2). Calorie and fat gram goals were adjusted throughout the 
course of the intervention as the participant fell into lower weight categories. The fat gram goals 
were set in accordance with USDA Dietary Guidelines that set a fat gram range of 20 - 25% of 
total calories97. 
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Table 2: Calorie and Fat Gram Goals by Baseline Body Weight 
Starting Weight (lbs) Calorie Goal Fat Gram Goal 
<175 1200 27g 
175-219 1500 33g 
220-249 1800 40g 
250+ 2100 47g 
 
Participants were also given a copy of The Calorie King Calorie, Fat, and Carbohydrate 
Counter, along with sample meal plans and recipes aimed at helping them in making healthy 
food choices. Food log diaries were provided throughout the 12-week period to track daily 
calorie and fat gram consumption over the course of a single week. These diaries were turned in 
every week to be reviewed and commented on by the interventionists. Suggestions were made in 
regards to: healthier food choices, portion control, etc. If a participant did not turn in a diary, or 
returned a semi-completed diary, an interventionist spoke to the participant either in person or 
over the phone to determine the cause of the problem or to offer modifications in completing the 
diary. 
3.6 DIET PLUS AEROBIC TRAINING 
Participants in the diet intervention who also receive aerobic training (DIET+AT) also received 
all of the educational components as described above for the DIET group. This group 
participated in supervised progressive aerobic training three days per week as shown in Table 3.  
Participants were required to attend three sessions per week at the University of Pittsburgh 
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Physical Activity and Weight Management Research Center. These supervised exercise sessions 
progressed from 60 to 180 minutes per week of moderate-intensity aerobic exercise (e.g., 
treadmill walking, recumbent cycling, adaptive motion trainer, elliptical trainer). Moderate-
intensity aerobic exercise was classified as 3 – 6 metabolic equivalents (METs), or three to six 
times the amount of work compared to a resting state. The American College of Sports Medicine 
and the American Heart Association recommend the equivalent of 450 – 750 MET minutes per 
week, or greater than 150 minutes per week 68. The intensity was set to increase at the rate 
prescribed to take full advantage of the relative brevity of this study.  
Participants were encouraged to not miss any training sessions throughout the course of 
the study. Attempts were made during the remainder of the week or following week to have the 
participant make up a missed session. These exercise sessions were conducted and supervised by 
trained graduate students at the University of Pittsburgh who were instructed not to provide any 
additional information relative to weight loss or dietary change to the participants during these 
sessions.   
Table 3: Aerobic Training Protocol for DIET+AT Group 
 Supervised Exercise 
 
Intervention Week 
 
Days per 
Week 
 
Minutes per 
Day 
 
Total Minutes 
per Week 
 
Exercise Intensity 
(% of age-predicted 
maximal heart rate) 
 
1 3 20 60 60-65 
2 3 30 90 60-65 
3 3 40 120 60-65 
4 3 50 150 65-70 
5-12 3 60 180 65-70 
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3.7 DIET PLUS RESISTANCE TRAINING 
Participants in the diet plus resistance training group (DIET+RT) also received all of the 
educational components of the DIET group. This group was prescribed a supervised resistance 
training protocol for a frequency of three days per week.  The protocol started the participants at 
a low volume of exercise at an intensity of 60-65% of 1-repetition maximum with low sets and 
repetitions and alternated volume and intensity throughout the intervention with a general trend 
toward increasing intensity, as outlined in the ACSM Position Stand: Progression Models in 
Resistance Training for Healthy Adults98.  Percent of 1-Repetition maximum was decreased 
before the participant increased sets and repetitions to allow the participant’s musculature to 
prepare for the added stress.  
Table 4 illustrates the resistance training protocol. The first week of training was devoted 
to familiarizing the participants with the resistance training equipment and ensuring proper safety 
protocol was followed when performing the exercises. The resistance exercises used icluded the 
following: Leg Press; Seated Row; Chest Press; Pulldown; Shoulder Press; Bicep Curl; Tricep 
Extension; Leg Extension; and Seated Leg Curl. Table 5 illustrates the timeline for various 
exercises in the resistance training intervention arm. 
In the event that a participant was uncomfortable with a particular exercise, that exercise 
was avoided or substituted for exercises that utilized resistance bands and tubing. Participants 
were encouraged to not miss any training sessions throughout the course of the study. Attempts 
were made during the remainder of the week or following week to have the participant make up 
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a missed session. The training sessions were conducted and supervised by graduate students of 
the University of Pittsburgh trained in the use of the equipment and qualified to respond to 
adverse events. 
Table 4: Resistance Training Protocol for DIET+RT Group 
 Supervised Exercise 
 
Intervention Week 
 
Days per 
Week 
 
Minutes per 
Day 
 
Total Minutes 
per Week 
 
Exercise Intensity 
(% of age-predicted 
maximal heart rate) 
 
1 3 20 60 60-65 
2 3 30 90 60-65 
3 3 40 120 60-65 
4 3 50 150 65-70 
5-12 3 60 180 65-70 
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Table 5: Timeline for Introduction of Various Exercises for DIET+RT Group 
Exercise Intervention Week 
 1 2 3 4 5 6 7 8 9 10 11 12 
Lower Body 
Exercises             
Leg Press X X X X X X X X X X X X 
Leg Extension    X X X X X X X X X 
Leg Curl    X X X X X X X X X 
Back Exercises             
Seated Row X X X    X X   X X 
Pulldown    X X X   X X   
Chest Press X X X X X X X X X X X X 
Shoulder 
Exercises             
Shoulder Press       X X X   X 
Upright Row 
(Dumbbell)    X X X     X  
Lateral Raise 
(Tubing) X X X       X   
Bicep Exercises             
Machine Curl    X X X       
Dumbbell Curl          X X X 
Tubing Curl       X X X    
Tricep Extension             
Machine    X X X    X  X 
Dumbbell       X X X  X  
 
3.8 STATISTICAL ANALYSES 
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) 
software, version 17.0. Statistical significance was set at p < 0.05.  Analyses were conducted 
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using individuals completing the assessment protocol at 0 and 12 weeks, and with intent-to-treat 
analysis carrying the baseline data forward.  The following analyses were performed: 
1. Descriptive analysis to examine the mean baseline characteristics (age, weight, BMI), 
body composition, daily physical activity, and dietary intake.   
2. Descriptive analysis to examine process measures, including: session attendance; 
dietary logging; self-reported caloric intake; and self-weighing frequency.  One-way 
analysis of variance (ANOVA) will be used to examine any differences in the process 
measures among groups 
3. 3 x2 repeated measures ANOVA will be performed on left ventricle morphology as a 
function of group and time to determine differences between the variables.  The main 
effect of time will be examined between 0 and 12 weeks; the main effect of group 
will examine any differences among randomized groups. The group x time interaction 
will be examined to determine patterns of difference among groups for weight loss 
between 0 and 12 weeks.  Post hoc pairwise comparisons will be used, if needed, to 
determine differences in weight loss between the randomized groups. 
4. 3 x 2 repeated measures ANOVA will be performed on weight loss as a function of 
group and time to determine differences between the variables.  The main effect of 
time will be examined between 0 and 12 weeks; the main effect of group will 
examine any differences among randomized groups. The group x time interaction will 
be examined to determine patterns of difference among groups for weight loss 
between 0 and 12 weeks.  Post hoc pairwise comparisons will be used, if needed, to 
determine differences in weight loss between the randomized groups. 
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5. 3 x 2 repeated measures ANOVA will be performed on dietary intake by group to 
determine if there are differences between the variables.  The main effect of time will 
determine any differences between 0 and 12 weeks.  The main effect of group will 
determine any differences between randomized group.  Group x time interaction will 
be examined to determine patterns of difference between the groups for dietary intake 
between 0 and 12 weeks.  Post hoc pairwise comparisons will be used, if needed, to 
determine differences in weight loss between the randomized groups 
6. 3 x 2 repeated measures ANOVA will be performed on body composition by group to 
determine if there are differences between the variables.  The main effect of time will 
determine any differences between 0 and 12 weeks.  The main effect of group will 
determine any differences between randomized groups.  Group x time interaction will 
be examined to determine patterns of difference between the groups for body 
composition between 0 and 12 weeks.  Post hoc pairwise comparisons will be used, if 
needed, to determine differences in weight loss between the randomized groups 
3.9 POWER ANALYSIS 
The primary aims of this study are to examine the effect of the interventions (DIET, DIET+AT, 
DIET+RT) on left ventricular changes that have been shown to be associated with increase risk 
of CVD.  The results from this study are intended to fulfill the dissertation requirement of the 
investigator and to provide important pilot data that can be used to support an appropriately 
powered larger study.  The pilot data of importance that will be obtained from this study will 
include the following: 1) effect sizes of differences between the intervention conditions for the 
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proposed left ventricular measures, 2) measures of compliance to the proposed doses of exercise 
in the DIET+AT and DIET+RT groups, 3) measures of compliance and feasibility for attendance 
at supervised exercise sessions, 4) data on recruitment of subjects to participate in a study of this 
nature.  Therefore, it is proposed that 30 subjects be recruited and complete the intervention, with 
10 subjects completing the study in each condition, and 5 subjects per study condition reporting 
for CMRI scans. Given the cost of each scan, performing more CMRI scans than proposed 
would be cost-prohibitive and would hinder the feasibility of this study.  
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4.0  RESULTS 
The purpose of this study was to examine the effect of weight loss induced by diet alone or in 
combination with either aerobic or resistance exercise on cardiovascular structure and function in 
Class II and III Obese women during a 12-week intervention. This was a pretest-posttest 
randomized controlled weight loss trial with assessments conducted at 0 and 12 weeks. The 
results of this study are presented below: 
4.1 SUBJECT CHARACTERISTICS 
A total of 24 Class II and III Obese women between the ages of 30 – 55 years with a body mass 
index (BMI) of 35.0 – 44.9 kg/m2 were randomized to this investigation. Assessment measures 
and intervention protocol were conducted at the University of Pittsburgh Physical Activity and 
Weight Management Research Center (PAWMRC) and University of Pittsburgh Medical Center 
Cardiovascular Magnetic Resonance Center (CMRC). Subjects had a mean age of 45.4 ± 6.9 
years and mean BMI of 39.0 ± 2.7 kg/m2 at the start of the intervention. A series of one-way 
analyses of variance (ANOVA) revealed no significant difference between treatment groups at 
baseline (p>0.061) for baseline demographics, body composition, dietary intake, physical 
activity, cardiorespiratory fitness, muscular strength or cardiovascular outcome measures. These 
data are presented in Table 6. 
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Table 6: Differences in Baseline Characteristics by Treatment Group 
Characteristics 
Total 
(N=24) 
(Mean±S.D.) 
DIET 
(N=8) 
(Mean±S.D.) 
DIET+AT 
(N=8) 
(Mean±S.D.) 
DIET+RT 
(N=8) 
(Mean±S.D.) 
p-value 
Age (years) 45.4 ± 6.9 46.6 ± 8.8 43.9 ± 5.9 45.5 ± 6.1 0.741 
Weight (kg) 104.2 ± 10.6 104.2 ± 11.3 107.2 ± 13.3 101.3 ± 6.8 0.757 
Body Mass Index (kg/m2) 39.0 ± 2.7 39.7 ± 2.2 39.0 ± 3.2 38.4 ± 2.7 0.622 
Waist Circumference (cm) 111.9 ± 7.2 115.3 ± 8.5 109.9 ± 7.1 110.6 ± 5.2 0.284 
Hip Circumference (cm) 128.6 ± 8.9 126.3 ± 3.9 132.6 ± 12.4 127.0 ± 7.9 0.316 
Waist-to-hip ratio 0.87 ± 0.07 0.91 ± 0.06 0.83 ± 0.07 0.87 ± 0.05 0.061 
Body Composition 
Regional %Fat (%) 
Tissue %Fat (%) 
48.9 ± 3.6 
50.2 ± 3.5 
48.2 ± 3.8 
49.5 ± 3.8 
49.8 ± 4.4 
51.1 ± 4.4 
48.6 ± 3.7 
49.9 ± 3.8 
0.715 
0.708 
Race 
%African American 
%Caucasian 
%Other 
 
20.8 (N=5) 
75.0 (N=18) 
4.2 (N=1) 
 
0.0 (N=0) 
100.0 (N=8) 
0.0 (N=0) 
25.0 (N=2) 
75.0 (N=6) 
0.0 (N=0) 
37.5 (N=3) 
50.0 (N=4) 
12.5 (N=1) 
0.508 
Dietary Intake (kcal/day) 
%Fat 
%Protein 
%Carbohydrate 
2056.0+644.2 
38.1+5.5 
15.2+3.3 
64.7+8.6 
2024.6+264.4 
37.2+2.2 
13.5+0.9 
49.3+3.5 
2088.3+276.4 
35.8+1.7 
15.4+0.8 
49.3+2.7 
2055.3+154.4 
41.3+1.5 
16.6+1.6 
41.5+2.2 
0.982 
0.107 
0.175 
0.108 
Eating Behavior Inventory 69.2 ± 9.7 67.6 ± 13.1 69.6 ± 8.9 70.6 ± 6.6 0.844 
Self Reported Physical 
Activity (kcal/week) 473.7 ± 445.6 322.1 ± 300.8 570.9 ± 516.7 528.1 ± 504.4 0.511 
VO2 at 85% APMHR* 
(ml/kg/min) 20.4 ± 3.6 21.8 ± 4.3 20.1 ± 3.7 19.2 ± 2.6 0.372 
Time to Reach 85% 
APMHR* HR (min) 5.8 ± 2.7 7.0 ± 2.7 4.9 ± 3.4 5.3 ± 1.7 0.286 
Left Ventricle Mass (g) 87.9 ± 16.3 94.5 ± 25.5 85.9 ± 14.3 83.9 ± 3.4 0.593 
Myocardial Fibrosis (%) 25.6 ± 2.0 24.2 ± 1.8 25.9 ± 1.8 26.8 ± 1.9 0.242 
End Systolic Volume (mL) 55.4 ± 15.9 51.9 ± 24.9 56.1 ± 12.9 57.9 ± 10.2 0.863 
End Diastolic Volume 
(mL) 141.5 ± 30.4 136.9 ± 48.2 141.4 ± 22.4 146.1 ± 21.4 0.790 
Ejection Fraction (%) 61.4 ± 5.2 63.3 ± 7.9 60.6 ± 3.9 60.4 ± 3.5 0.711 
*APMHR = Age Predicted Maximal Heart Rate (220-age) 
4.2 RETENTION 
Figure 4 illustrates overall retention of the cohort. One subject in the DIET group was lost due to 
relocation while the other was lost for unknown reasons. Neither of the subjects lost in the 
DIET+AT group gave reasons for their discontinuation in the study, while both subjects in the 
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DIET+RT group were lost due to injuries sustained outside of the intervention. Overall, retention 
rates for each of the three groups were identical (N=6, 75%).  
The 18 subjects who completed baseline and final assessments at PAWMRC and 16 who 
completed final scans at CMRC will be referred to as “completers”. Subjects who did not 
complete final assessments at PAWMRC (N=6) will be referred to as “non-completers”. Data for 
two subjects who did not complete their 12-week scans at CMRC were not available and 
therefore will not be included in the results. One subject was unable to reschedule her 
appointment after difficulty placing the intravenous (IV) line during her first scheduled 
appointment at week 12. The other participant encountered claustrophobia during the baslien 
scan and was uncomfortable with another scan at week 12. Baseline characteristics between 
completers and non-completers are presented in Table 7. There was a trend toward a significance 
difference observed for waist circumference (completers: 113.6 ± 7.2cm, non-completers: 107.2 
± 4.6cm; p=0.056), however no significant differences were observed for the other baseline 
characteristics (p>0.56).  
When examined by treatment group, non-completers in the DIET group (24.5 ± 
1.3ml/kg/min) had significantly higher VO2 at 85% age-predicted maximal heart rate (APMHR) 
than the completers (20.9 ± 4.6ml/kg/min; p<0.05). Inversely, completers in the DIET+AT group 
(21.1 ± 3.8ml/kg/min) had significantly higher VO2 at 85% APMHR than the non-completers 
(17.2 ± 0.4ml/kg/min; p<0.05). Non-completers in the DIET and DIET+RT groups had 
significantly longer time to reach 85% APMHR (8.8 ± 0.7min and 4.7 ± 0.0min, respectively) 
compared to completers in the DIET (6.4 ± 2.9min) and DIET+RT (5.0 ± 1.9min) groups 
(p<0.05). Inversely, completers in the DIET+AT group had significantly longer time to reach 
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85% of APMHR compared to the non-completers (5.3 ± 4.0min and 3.7 ± 0.5min, respectively; 
p<0.05). These data are presented in Table 8. 
 
Figure 4: Study Retention and Enrollment Across Groups 
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Table 7: Differences in Baseline Characteristics by Completers and Non-Completers 
Characteristics 
Total 
(N=24) 
(Mean±S.D.) 
Completers 
(N=18) 
(Mean±S.D.) 
Non-
Completers 
(N=6) 
(Mean±S.D.) 
p-value 
Age (years) 45.4 ± 6.9 44.9 ± 6.6 46.7 ± 7.9 0.598 
Weight (kg) 104.2 ± 10.6 105.0 ± 10.9 101.9 ± 10.1 0.550 
Body Mass Index (kg/m2) 39.0 ± 2.7 39.3 ± 2.6 38.1 ± 2.9 0.352 
Waist Circumference (cm) 111.9 ± 7.2 113.6 ± 7.2 107.2 ± 4.6 0.056 
Hip Circumference (cm) 128.6 ± 8.9 129.3 ± 9.5 126.7 ± 7.1 0.551 
Waist-to-hip ratio 0.87 ± 0.07 0.88 ± 0.07 0.85 ± 0.04 0.280 
Body Composition 
%Fat - Regional 
%Fat - Tissue 
48.9 ± 3.6 
50.2 ± 3.5 
48.9 ± 4.0 
50.2 ± 4.0 
48.7 ± 3.5 
50.0 ± 3.5 
0.937 
0.924 
Race 
%African American 
%Caucasian 
%Other 
 
20.8 (N=5) 
75.0 (N=18) 
4.2 (N=1) 
27.8 (N=5) 
72.2 (N=13) 
0.0 (N=0) 
0.0 (N=0) 
83.3 (N=5) 
16.7 (N=1) 
0.339 
Dietary Intake (kcal/day) 
%Fat 
%Protein 
%Carbohydrate 
2056.0+644.2 
38.1+5.5 
15.2+3.3 
64.7+8.6 
2201.9+157.3 
38.6+1.4 
15.8+0.8 
45.9+2.1 
1618.5+120.9 
36.4+1.9 
13.3+1.1 
49.3+3.1 
0.052 
0.407 
0.103 
0.418 
Eating Behavior Inventory 69.2 ± 9.7 68.5 ± 9.8 71.2 ± 9.7 0.577 
Self Reported Physical Activity 
(kcal/week) 473.7 ± 445.6 466.4 ± 428.9 495.5 ± 535.8 0.894 
VO2 at 85% APMHR* (ml/kg/min) 20.4 ± 3.6 20.2 ± 3.8 20.9 ± 3.4 0.701 
Time to Reach 85% APMHR* (min) 5.8 ± 2.7 5.8 ± 2.9 6.3 ± 2.3 0.597 
Left Ventricle Mass (g)¥ 88.1 ± 15.6 87.9 ± 16.3 89.6 ± 12.2 0.895 
Myocardial Fibrosis (%)¥ 25.5 ± 2.1 25.6 ± 2.0 24.4 ± 2.8 0.462 
End Systolic Volume (mL) ¥ 55.1 ± 15.0 55.4 ± 15.9 53.3 ± 0.6 0.858 
End Diastolic Volume (mL) ¥ 143.1 ± 28.9 141.5 ± 30.4 155.9 ± 7.1 0.524 
Ejection Fraction (%)¥ 61.9 ± 5.1 61.4 ± 5.2 65.8 ± 1.9 0.260 
*APMHR = Age Predicted Maximal Heart Rate (220-age) 
¥Data for only 18 subjects is available for CMRI (16 completers, 2 non-completers)  
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Table 8: Baseline Characteristics by Treatment Group and Completion 
 DIET DIET+AT DIET+RT 
Characteristics 
Completers 
(N=6) 
(Mean±S.D.) 
Non-
Completers 
(N=2) 
(Mean±S.D) 
Completers 
(N=6) 
(Mean±S.D.) 
Non-
Completers 
(N=2) 
(Mean±S.D) 
Completers 
(N=6) 
(Mean±S.D.) 
Non-Completers 
(N=2) 
(Mean±S.D) 
Age (years) 48.7±7.8 40.3±11.4 41.9±5.2 49.8±4.9 44.1±5.8 50.0±6.4 
Weight (kg) 105.8±12.7 99.2±5.1 108.9±12.0 101.9±21.1 100.2±7.6 104.6±2.2 
Body Mass Index 
(kg/m2) 40.3±2.1 38.0±2.0 39.0±3.1 39.3±5.0 38.8±2.7 37.2±2.9 
Waist Circumference 
(cm) 118.3±7.1 106.2±5.8 110.2±7.9 109.3±6.3 112.2±4.7 106.1±4.6 
Hip Circumference 
(cm) 127.6±3.6 122.4±2.0 133.6±13.2 129.4±13.4 126.6±9.2 128.3±3.3 
Waist-to-hip ratio 0.93±0.05 0.87±0.06 0.83±0.09 0.85±0.04 0.89±0.05 0.83±0.01 
Body Composition 
%Fat - Regional 
%Fat - Tissue 
49.2±3.1 
50.5±3.1 
45.3±4.3 
46.5±4.3 
49.8±5.2 
51.1±5.2 
49.6±1.3 
50.8±1.4 
47.7±3.9 
49.0±4.0 
51.4±1.0 
52.7±1.0 
Race 
%African American 
%Caucasian 
%Other 
0.0 (N=0) 
100.0 (N=6) 
0.0 (N=0) 
0.0 (N=0) 
100.0 (N=2) 
0.0 (N=0) 
16.7 (N=1) 
83.3 (N=5) 
0.0 (N=0) 
50.0 (N=1) 
50.0 (N=1) 
0.0 (N=0) 
50.0 (N=3) 
50.0 (N=3) 
0.0 (N=0) 
0.0 (N=0) 
50.0 (N=1) 
50.0 (N=1) 
Dietary Intake 
(kcal/day) 2216.2±774.7 1449.9±184.1 2183.5±899.9 1802.7±107.3 2206.0±323.1 1603.1±517.7 
Eating Behavior 
Inventory 67.8±14.7 67.0±11.3 67.5±7.0 76.0±14.1 70.6±7.0 70.5±7.8 
Self Reported 
Physical Activity 
(kcal/week) 
350.2±349.5 238.0±59.4 471.0±358.4 870.5±993.5 578.2±586.1 378.0±59.4 
VO2 at 85% 
APMHR*(ml/kg/min) 20.9±4.6 24.5±1.3
a 21.1±3.8 17.2±0.4a 18.6±2.7 21.0±1.1 
Time to Reach 85% 
APMHR* (min) 6.39±2.87 8.8±0.7
a 5.3±3.9 3.7±0.5a 5.0±1.9 6.3±0.0a 
Left Ventricle Mass 
(g) Ω 94.5±25.5 ---- 85.9±14.3 ---- 83.9±3.4 ---- 
Myocardial Fibrosis 
(%)Ω 24.2±1.8 ---- 25.9±1.8 ---- 26.8±1.9 ---- 
End Systolic Volume 
(mL) Ω 51.9±24.9 ---- 56.1±12.9 ---- 57.9±10.2 ---- 
End Diastolic 
Volume (mL) Ω 136.9±48.2 ---- 141.4±22.4 ---- 146.1±21.4 ---- 
Ejection Fraction 
(%)Ω 63.3±7.9 ---- 60.6±3.9 ---- 60.4±3.4 ---- 
amean difference significant at p < 0.05 
*APMHR = Age Predicted Maximal Heart Rate (220-age) 
ΩOnly 5 subjects from DIET and DIET+RT completed CMRI at Week 12 
NOTE: Only data for the 18 study completers are available for CMRI data (1 non-completer in 
DIET and DIET+RT each) 
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4.3 CHANGES IN BODY WEIGHT AND BODY MASS INDEX (BMI) 
A 3×2 repeated measures ANOVA was performed on body weight and body mass index as a 
function of time and treatment. Completers analysis revealed significant weight loss from 0 to 12 
weeks in the DIET (-3.2 ± 2.4kg), DIET+AT (-5.9 ± 3.1kg) and DIET+RT (-4.9 ± 4.1kg) 
(p<0.001) groups, however the differences between groups (p=0.400) and group by time 
interaction (p=0.376) were not significant (Figure 5). Similarly, analyses for BMI revealed a 
significant reduction in BMI for the DIET (-1.2 ± 0.9kg/m2), DIET+AT (-2.1 ± 1.1kg/m2) and 
DIET+RT (-1.9 ± 1.7kg/m2) groups from 0 to 12 weeks (p<0.001) but no significant group 
(p=0.387) or group by time interaction (p=0.468). These data are presented in Table 9. 
Moreover, percent total weight loss across all groups was -4.7 ± 3.9% with no differences 
between treatment groups (DIET: -3.0 ± 2.1%, DIET+AT: -5.4 ± 2.8%, DIET+RT: -4.7 ± 3.9%; 
p=0.380). These data are represented in Figure 6. 
Intent-to-treat analyses were also conducted for all outcome data (Table 10). This 
analysis included the baseline value being carried forward for the six non-completers to assume 
no change. A 3×2 repeated measures ANOVA revealed a significant time effect of weight 
between the DIET (-2.4 ± 2.5kg), DIET+AT (-4.4 ± 3.8kg) and DIET+RT (-3.7 ± 4.2kg) 
(p<0.001) treatment groups but no significant group effect (p=0.582) or group by time 
interaction (p=0.521) (Figure 5). Likewise, BMI analysis revealed a significant reduction in BMI 
for the DIET (-0.9 ± 0.9kg/m2), DIET+AT (-1.6 ± 1.3kg/m2) and DIET+RT (-1.4 ± 1.7kg/m2) 
(p<0.001) treatment groups, but no group effect (p=0.478) or group by time interaction 
(p=0.593). Percent total weight loss across all groups was -3.5 ± 3.3% with no differences 
between treatment groups (DIET: -3.0 ± 2.8%, DIET+AT: -4.1 ± 3.5%, DIET+RT: -3.5 ± 3.9%; 
p=0.839) (Figure 6). 
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Table 9: 12 Week Outcome Differences Between Treatment Group - Completers 
Outcome Variable 
DIET 
(N=6) 
(Mean±S.D.) 
DIET+AT 
(N=6) 
(Mean±S.D) 
DIET+RT 
(N=6) 
(Mean±S.D.) 
Group 
Effect 
Time 
Effect 
Group x Time 
Effect 
Weight (kg) 
0 Weeks 
12 Weeks 
105.8±12.7 
102.7±12.5 
108.9±12.0 
103.1±12.2 
100.2±7.6 
95.4±6.1 
0.400 <0.001 0.376 
Body Mass Index 
(kg/m2) 
0 Weeks 
12 Weeks 
40.3±2.1 
39.1±2.2 
39.0±3.1 
36.9±3.6 
38.8±2.7 
36.9±1.8 
 
0.387 
 
<0.001 
 
0.468 
Dietary Intake 
(kcal/day) 
0 Weeks 
12 Weeks 
2216.2±774.7 
1490.6±593.2 
2183.5±899.9 
1630.1±634.8 
2206.0±323.1 
1565.9±336.7 
0.985 0.001 0.905 
Eating Behavior 
Inventory 
0 Weeks 
12 Weeks 
67.8±14.7 
88.7±7.7 
67.5±7.0 
82.8±7.5 
70.5±6.3 
96.5±7.0 
 
0.133 
 
<0.001 
 
0.291 
Self Reported Physical 
Activity (kcal/week) 
0 Weeks 
12 Weeks 
350.2±349.5 
522.3±849.7 
471.0±358.4 
925.8±780.3 
578.2±586.1 
1084.0±1009.6 
 
0.506 
 
.057 
 
0.730 
VO2 at 85% APMHR* 
(ml/kg/min) 
0 Weeks 
12 Weeks 
20.9±4.6 
21.3±4.6 
21.1±3.8 
22.2±3.9 
18.6±2.7 
19.6±2.1 
 
0.454 
 
0.128 
 
0.883 
Time to Reach 85% 
APMHR* (min) 
0 Weeks 
12 Weeks 
6.4±2.9 
7.3±2.8 
5.3±4.0 
7.9±3.5 
5.0±1.9 
6.1±1.1 
 
0.690 
 
<0.001 
 
0.094 
Muscular Strength by 
1-RM (kg) 
Leg Press 
0 Weeks 
12 Weeks 
Chest Press 
0 Weeks 
12 Weeks 
Seated Row 
0 Weeks 
12 Weeks 
50.0±26.4 
52.6±20.8 
 
31.0±11.6 
38.6±13.5 
 
32.2±10.5 
40.1±11.8 
78.8±43.5 
75.8±44.0 
 
46.2±15.5 
49.2±15.5 
 
43.2±20.5 
46.6±17.0 
71.2±46.0 
94.3±52.9 
 
42.0±10.1 
50.8±10.2 
 
41.7±15.0 
51.9±13.0 
 
 
0.364 
 
 
0.189 
 
 
0.431 
 
 
 
0.098 
 
 
<0.001 
 
 
<0.001 
 
 
 
0.060 
 
 
0.179 
 
 
0.204 
 
*APMHR = Age Predicted Maximal Heart Rate (220-age) 
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Table 10: 12 Week Outcome Differences Between Treatment Group - Intent-to-Treat 
Outcome Variable 
DIET 
(N=8) 
(Mean±S.D.) 
DIET+AT 
(N=8) 
(Mean±S.D) 
DIET+RT 
(N=8) 
(Mean±S.D.) 
Group 
Effect 
Time 
Effect 
Group x Time 
Effect 
Weight (kg) 
0 Weeks 
12 Weeks 
104.2±11.3 
101.8±10.9 
107.2±13.3 
102.8±13.0 
101.3±6.8 
97.7±6.7 
0.582 <0.001 0.521 
Body Mass Index 
(kg/m2) 
0 Weeks 
12 Weeks 
39.7±2.2 
38.8±2.1 
39.0±3.2 
37.5±3.7 
38.4±2.7 
36.9±1.9 
 
0.478 
 
<0.001 
 
0.593 
Dietary Intake 
(kcal/day) 
0 Weeks 
12 Weeks 
2024.6±747.9 
1118.0±852.9 
2088.3±781.8 
1222.5±925.9 
2055.3±436.8 
1171.6±817.8 
 
0.969 
 
<0.001 
 
0.994 
Eating Behavior 
Inventory 
0 Weeks 
12 Weeks 
67.6±13.1 
83.3±12.7 
69.6±8.9 
81.1±8.9 
70.5±6.1 
90.0±13.7 
 
0.437 
 
<0.001 
 
0.515 
Self Reported Physical 
Activity (kcal/week) 
0 Weeks 
12 Weeks 
322.1±300.8 
451.3±730.4 
570.9±516.7 
912.0±759.3 
528.1±504.4 
907.5±914.0 
 
0.379 
 
0.055 
 
0.735 
VO2 at 85% APMHR* 
(ml/kg/min) 
0 Weeks 
12 Weeks 
21.8±4.3 
22.1±4.2 
20.1±3.7 
20.9±4.1 
19.2±2.6 
19.9±1.9 
 
0.397 
 
0.122 
 
0.882 
Time to Reach 85% 
APMHR* (min) 
0 Weeks 
12 Weeks 
7.0±2.7 
7.7±2.5 
4.9±3.4 
6.8±3.6 
5.3±1.7 
6.1±1.0 
 
0.395 
 
0.001 
 
0.161 
Muscular Strength by 
1-RM (kg) 
Leg Press 
0 Weeks 
12 Weeks 
Chest Press 
0 Weeks 
12 Weeks 
Seated Row 
0 Weeks 
12 Weeks 
55.4±35.8 
57.4±32.7 
 
33.8±15.1 
39.5±15.5 
 
33.5±11.4 
39.5±12.1 
71.6±40.4 
69.3±40.2 
 
44.0±13.7 
46.3±14.2 
 
39.8±18.6 
42.3±16.6 
71.3±40.3 
88.6±47.1 
 
41.2±10.6 
47.7±12.0 
 
41.8±14.3 
49.5±13.6 
 
 
0.485 
 
 
0.384 
 
 
0.458 
 
 
 
0.109 
 
 
<0.001 
 
 
0.001 
 
 
 
0.067 
 
 
0.282 
 
 
0.296 
 
*APMHR = Age Predicted Maximal Heart Rate (220-age) 
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NOTE: Significant time effect (p<0.001) 
NOTE: Between group comparisons were not statistically significant 
 
Figure 5: Weight Loss Across Treatment Groups - Completers and Intent-to-Treat 
NOTE: Significant time effect (p<0.001) 
NOTE: Between group comparisons were not statistically significant 
 
Figure 6: Percent Weight Loss Across Treatment Groups - Completers and Intent-to-Treat 
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4.4 CHANGES IN DIETARY INTAKE AND EATING BEHAVIORS 
A 3×2 repeated measures ANOVA showed a significant reduction in dietary intake for 
completers from 0 to 12 weeks in all treatment groups (p=0.001). Weight loss eating behaviors, 
as measured by the Eating Behavior Inventory, significantly improved in all treatment groups 
from 0 to 12 weeks (p<0.001). No differences were observed between groups (p=0.133). See 
Table 9. Not shown are changes in macronutrient composition among treatment groups. 
Completers analysis revealed a significant reduction in calorie intake and percent of calories 
from fat and a significant increase in percent of calories from carbohydrates (p<0.024) across all 
groups. There was no significant change in protein intake over 12 weeks (p=0.571). 
 Intent-to-treat analysis showed significant reductions in 12 week dietary intake 
from baseline in all groups (p=0.001). Similarly, weight loss eating behaviors improved over 12 
weeks (p<0.001), although there were no group differences (p=0.478). See Table 9. 
Macronutrient composition was consistent with completers analysis when examined intent-to-
treat.  
4.5 CHANGES IN PHYSICAL ACTIVITY 
Weekly self-reported energy expenditure (kcal/week) in leisure-time physical activity was 
assessed using the Paffenbarger Physical Activity Questionnaire. Results from a 3×2 repeated 
measures ANOVA showed completers self-reported greater weekly caloric expenditure at 12 
weeks then at baseline (p=0.057). Although there were no significant group differences 
(p=0.506), subjects in the exercise conditions reported expending nearly 400-500 kilocalories 
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more per week than the diet only group (See Table 9). Intent-to-treat analysis revealed similar 
findings for time (p=0.055) and group (p=0.379) effects. 
4.6 CHANGES IN CARDIORESPIRATORY FITNESS 
Cardiorespiratory fitness was measured during a submaximal graded exercise test and expressed 
as: oxygen consumption at 85% APMHR (VO2) and time to reach 85% APMHR expressed as 
minutes. A repeated measures 3×2 ANOVA revealed no significant differences in the change of 
VO2 at 85% APMHR from 0 to 12 weeks for the DIET (0.48 ± 2.6ml/kg/min), DIET+AT (1.0 ± 
2.2ml/kg/min) and DIET+RT (0.9 ± 1.8ml/kg/min) (p=0.883) treatment groups with no 
significant group effect (p=0.454) or group by time effect (p=0.883). While there was also no 
significant group or group by time effect for time to reach 85% APMHR (p=0.690 and 0.094, 
respectively), there was a significant time effect (p<0.001) for the DIET (0.9 ± 0.7min), 
DIET+AT (2.6 ± 2.0min) and DIET+RT (1.1 ± 0.9min) intervention groups (Table 9). 
Furthermore, cardiorespiratory fitness was not significantly different between groups at week 12 
(p=0.214) when examined in absolute terms (mL/min). Interestingly, subjects in the DIET and 
DIET+AT groups reduced absolute VO2 (-20.9 ± 255.8mL/min and -10.2 ± 243.2mL/min, 
respectively) at week 12.  
Intent-to-treat analysis revealed no significant change from 0 to 12 weeks in oxygen 
consumption in the DIET (0.4 ± 2.2ml/kg/min), DIET+AT (0.8 ± 1.9ml/kg/min) and DIET+RT 
(0.7 ± 1.6ml/kg/min) (p=0.122) treatment groups. Moreover, there were no significant group 
differences (p=0.397) or group by time interaction (p=0.882). Further analyses showed a 
significant increase in time to reach 85% of maximal heart rate in the DIET (0.7 ± 0.7min), 
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DIET+AT (1.9 ± 2.1min) and DIET+RT (0.8 ± 0.9min) (p<0.001) intervention groups but no 
significant group effect (p=0.395) or group by time interaction (p=0.161) as shown in Table 10. 
4.7 CHANGES IN MUSCULAR STRENGTH 
Muscular strength was assessed utilizing three different exercises: leg press, chest press, and 
seated row. The maximal weight lifted one time was recorded as the one-repetition maximum. A 
3×2 repeated measures ANOVA showed that change in weight lifted on the leg press for 
completers in the DIET, DIET+AT, and DIET+RT (p=0.098) was 2.6 ± 21.5kg, -3.0 ± 20.4kg, 
and 23.1 ± 9.7kg, respectively (p=0.098). Completers did have a significant increase in weight 
lifted on the chest press (DIET: 7.6 ± 5.3kg; DIET+AT: 3.0 ± 6.2kg; DIET+RT: 8.7 ± 4.2kg) and 
seated row (DIET: 8.0 ± 5.7kg; DIET+AT: 3.4 ± 8.2kg; DIET+RT: 10.2 ± 4.7kg) (p<0.001) from 
baseline. Moreover, while the changes in strength are not statistically significant between groups, 
subjects in the resistance training group showed greater improvements in all strength measures. 
Data are shown in Table 9. Changes in maximal strength can be seen in Figures 7 - 9. 
Similar results are shown for intent-to-treat analysis of the strength measures (Table 10). 
No significant change was observed from 0 to 12 weeks for the weight lifted on the leg press 
(p=0.109) for the DIET (2.0 ± 18.1kg), DIET+AT (-2.3 ± 17.3kg) or DIET+RT (17.3 ± 14.2kg) 
treatment groups. Maximal weight lifted on the chest press at 12 weeks increased significantly 
(p<0.001) for the DIET (5.7 ± 5.7kg), DIET+AT (2.3 ± 5.4kg) and DIET+RT (6.5 ± 5.4kg) 
treatment groups. Likewise, maximal weight lifted on the seated row significantly increased 
(p=0.001) at 12 weeks for the DIET (6.0 ± 6.0kg), DIET+AT (2.5 ± 7.1kg) and DIET+RT (7.7 ± 
6.2kg) treatment groups compared to baseline. There were no between group differences 
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(p>0.384) or group by time interactions (p>0.067) for the leg press, chest press, or seated row 
(See Figure 7 - 9). 
 
NOTE: Time effect not statistically significant 
NOTE: Between group comparisons were not statistically significant 
 
Figure 7: Leg Press Strength Change - Completers and Intent-to-Treat 
 
NOTE: Time effect statistically significant (p<0.001) 
NOTE: Between group comparisons not statistically significant. 
 
Figure 8: Chest Press Strength Change - Completers and Intent-to-Treat 
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NOTE: Time effect statistically significant (p<0.001) 
NOTE: Between group comparisons not statistically significant  
Figure 9: Seated Row Strength Change - Completers and Intent-to-Treat 
4.8 CHANGES IN ANTHROPOMETRIC MEASUREMENTS AND BODY 
COMPOSITION 
Anthropometric measurements included a circumference measure at the waist and another at the 
hip. Body composition was determined using the iDXA with body fat percentage, fat and lean 
mass, bone mineral content, and bone mineral density extracted. A 3×2 mixed ANOVA for 
completers revealed a significant decrease from 0 to 12 weeks in waist (DIET: -4.4 ± 6.1cm; 
DIET+AT: -4.9 ± 4.2cm; DIET+RT: -7.8 ± 4.0cm) and hip (DIET: -4.0 ± 2.7cm; DIET+AT: -5.4 
± 4.8cm; DIET+RT: -7.8 ± 3.9cm) circumferences (p<0.001). Waist circumference was 
significantly different between treatment groups (p=0.047) as shown in Table 11. Post hoc 
analysis showed the DIET+RT group had significantly lower waist circumferences than the 
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DIET+AT group (p=0.005) and the DIET+AT group had significantly lower waist 
circumferences than the DIET group (p=0.037) at 12 weeks. There were no significant changes 
in bone mineral content or bone mineral density from baseline (p>0.064) or between groups 
(p>0.789) at 12 weeks. Body fat percentage significantly decreased in the DIET (-0.6 + 1.2%), 
DIET+AT (-1.5 ± 1.6%) and DIET+RT (-1.6 ± 0.15%) treatment groups over time (p=0.003). 
There was no group (p=0.625) or interaction (p=0.437) effect at 12 weeks for body fat 
percentage. Fat mass significantly decreased from 0 to 12 weeks in all treatment groups (DIET: -
2.2 ± 2.3kg; DIET+AT: -3.6 ± 2.4kg; DIET+RT: -3.8 ± 3.4kg) (p<0.001) and lean mass showed 
a trend (p=0.053) towards reduction (DIET: -0.9 ± 0.9kg; DIET+AT: -0.6 ± 2.4kg, DIET+RT: -
0.9 ± 1.2kg). Neither fat nor lean mass was different between groups at 12 weeks (p=0.330 and 
0.822, respectively). See Table 11.  
Intent-to-treat analysis revealed similar results for decreases in waist (p<0.001) and hip 
(0<0.001) circumference at 12 weeks for the DIET (waist:-3.3 ± 5.5cm; hip:-3.0 ± 2.9cm), 
DIET+AT (waist: -3.6 ± 4.2cm; hip:-4.1 ± 4.8cm) and DIET+RT (waist: -5.9 ± 4.9cm; hip: -4.7 
± 4.1cm) treatment groups. As shown in Table 12, body fat percentage (p=0.003), fat mass 
(p<0.001) and lean mass (p=0.05) was significantly lower at week 12 for all treatment groups. 
No other treatment or interaction effects were seen. 
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Table 11: 12 Week Body Composition Defferences Between treatment Group - Completers 
Outcome Variable 
DIET 
(N=6) 
(Mean±S.D.) 
DIET+AT 
(N=6) 
(Mean±S.D) 
DIET+RT 
(N=6) 
(Mean±S.D.) 
Group 
Effect 
Time 
Effect 
Group x Time 
Effect 
Waist Circumference 
(cm) 
0 Weeks 
12 Weeks 
118.3±7.1 
113.9±3.4 
110.2±7.9 
105.4±7.6 
112.2±4.7 
104.4±6.1 
 
0.047 
 
<0.001 
 
0.440 
Hip Circumference (cm) 
0 Weeks 
12 Weeks 
127.6±3.6 
123.6±3.7 
133.6±13.2 
128.2±12.9 
126.6±9.2 
120.3±6.6 
 
0.352 
 
<0.001 
 
0.583 
Waist-to-hip ratio 
0 Weeks 
12 Weeks 
0.93±0.05 
0.92±0.03 
0.83±0.09 
0.83±0.07 
0.89±0.05 
0.87±0.06 
0.040 0.197 0.628 
Bone Mineral Content 
(kg) 
0 Weeks 
12 Weeks 
 
2.7±0.5 
2.7±0.5 
 
2.8±0.4 
2.8±0.4 
 
2.7±0.4 
2.7±0.4 
 
0.789 
 
0.064 
 
0.601 
Bone Mineral Density 
(g/cm3) 
0 Weeks 
12 Weeks 
 
1.32±0.14 
1.32±0.13 
1.32±0.14 
1.32±0.14 
1.33±0.13 
1.32±0.12 
0.978 
 
 
0.753 
 
 
0.533 
 
Body Fat – Regional 
(%)* 
0 Weeks 
12 Weeks 
49.2±3.1 
48.6±3.4 
49.8±5.2 
48.3±6.0 
47.7±3.9 
46.1±3.0 
 
0.617 
 
0.002 
 
0.441 
Body Fat – Tissue (%)° 
0 Weeks 
12 Weeks 
50.5±3.1 
49.9±3.3 
51.2±5.2 
49.6±6.0 
49.0±4.0 
47.4±3.1 
0.625 
 
0.003 
 
0.437 
 
Fat Mass (kg) 
0 Weeks 
12 Weeks 
51.3±6.3 
49.2±6.1 
54.2±10.2 
50.6±11.8 
51.0±7.8 
43.7±4.5 
 
0.330 
 
 
<0.001 
 
 
0.560 
 
Lean Mass (kg) 
0 Weeks 
12 Weeks 
50.6±7.4 
49.6±7.3 
51.2±5.7 
50.6±6.9 
49.2±4.6 
48.3±3.9 
 
0.822 
 
 
0.053 
 
 
0.921 
 
*body fat percentage with bone mineral content included 
°body fat percentage without bone mineral content included 
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Table 12: 12 Week Body Composition Differences Between Treatment Group - Intent-to-Treat 
Outcome Variable 
DIET 
(N=8) 
(Mean±S.D.) 
DIET+AT 
(N=8) 
(Mean±S.D) 
DIET+RT 
(N=8) 
(Mean±S.D.) 
Group Effect Time Effect 
Group x Time 
Effect 
Waist Circumference (cm) 
0 Weeks 
12 Weeks 
115.3±8.5 
111.9±5.1 
110.0±7.1 
106.3±7.1 
110.6±5.2 
104.8±5.5 
 
0.119 
 
<0.001 
 
0.542 
Hip Circumference (cm) 
0 Weeks 
12 Weeks 
126.3±3.9 
123.3±3.3 
132.6±12.4 
128.5±12.1 
127.0±7.9 
122.3±6.8 
 
0.289 
 
<0.001 
 
0.697 
Waist-to-hip ratio 
0 Weeks 
12 Weeks 
0.91±0.06 
0.91±0.04 
0.83±0.07 
0.83±0.06 
0.87±0.05 
0.86±0.05 
0.041 0.155 0.775 
Bone Mineral Density 
(g/cm3) 
0 Weeks 
12 Weeks 
1.32±0.12 
1.32±0.11 
1.31±0.15 
1.31±0.15 
1.32±0.11 
1.32±0.11 
 
0.966 
 
0.840 
 
0.424 
Bone Mineral Content (kg) 
0 Weeks 
12 Weeks 
2.7±0.4 
2.7±0.4 
2.7±0.5 
2.7±0.5 
2.7±0.3 
2.7±0.3 
 
0.953 
 
0.062 
 
0.608 
Body Fat – Regional (%)* 
0 Weeks 
12 Weeks 
48.2±3.6 
47.7±3.6 
49.8±4.4 
48.6±5.1 
48.6±3.7 
47.4±3.6 
 
0.786 
 
0.003 
 
0.501 
Body Fat - Tissue (%)° 
0 Weeks 
12 Weeks 
49.5+3.5 
49.0+3.6 
51.2+4.4 
50.0+5.1 
50.0±3.8 
48.8±3.6 
 
0.786 
 
0.003 
 
0.483 
Fat Mass (kg) 
0 Weeks 
12 Weeks 
49.7±6.6 
48.1±6.1 
53.2±9.9 
50.5±10.9 
48.9±5.9 
46.1±5.9 
0.518 <0.001 0.648 
Lean Mass (kg) 
0 Weeks 
12 Weeks 
50.7±6.3 
50.0±6.2 
50.5±6.0 
50.1±6.8 
48.8±4.0 
48.2±3.3 
0.748 0.050a 0.923 
*body fat percentage with bone mineral content included 
°body fat percentage without bone mineral content included 
4.9 CHANGES IN CARDIAC STRUCTURE AND FUNCTION 
Sixteen subjects completed baseline and 12 week scans at CMRC (DIET=5, DIET+AT=6, 
DIET+RT=5). The subject in the DIET group was lost due to claustrophobia while the subject in 
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the DIET+RT group was lost for unknown reasons. Data are presented for completers only and 
are seen in Table 13. 
4.9.1 Left Ventricular Mass 
The pattern of change in left ventricular mass (LVM) between treatment groups was significantly 
different at week 12 from baseline (p=0.007) (See Figure 10). Subjects in the DIET (-7.2 ± 3.9g) 
group had a trend toward statistically significant greater reductions from baseline compared to 
the DIET+RT group (-0.2 ± 3.5g) (p=0.059) and statistically significant greater reduction than 
the DIET+AT group (2.3 ± 4.7g) (p=0.008). Change scores for the DIET+AT and DIET+RT 
groups were not statistically significant (p=0.616). At week 12, LVM was not significantly 
different between groups (p=0.784). 
 
NOTE: LVM change score statistically significant (DIET>DIET+AT and DIET+RT, p=0.007) 
NOTE: Between group comparison not statistically significant 
Figure 10: Left Ventricular Mass Change Scores - Completers 
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4.9.2 Myocardial Fibrosis 
There was a significant treatment effect (p=0.010) for myocardial extravascular extracellular 
volume fraction (Ve), i.e. myocardial fibrosis. Subjects in the DIET+RT group had a 
significantly higher percentage of Ve at 12 weeks (27.9±1.5%) than the DIET and DIET+AT 
treatment groups. While not statistically significant, there was a reduction in Ve in the DIET 
group (-0.2 ± 1.8%) and an increase in both the DIET+AT (0.6 ± 1.1%) and DIET+RT (1.2 ± 
1.3%) treatment groups from 0 to 12 weeks (p=0.433). See Figure 11. 
 
NOTE: Between group comparison statistically significant (DIET+RT>DIET+AT, p<0.05) 
NOTE: Time effect not statistically significant 
Figure 11: Myocardial Fibrosis Change Scores - Completers 
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not significantly different, Figure 12 shows that there are quantifiable differences in the change 
scores. Subjects in the exercise groups appear to have a greater increase in end diastolic volume. 
Additionally, end systolic volume decreased in the DIET+AT group and increased in the DIET 
and DIET+RT groups. Ejection fraction increased in the exercise conditions and decreased in the 
diet only group. 
 
NOTE: Between group comparisons not statistically significant 
NOTE: Time effect not statistically significant 
Figure 12: Volumetric Measurement Change Scores – Completers 
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Table 13: Cardiac MRI Differences Between Treatment Group at 12 Weeks 
Outcome Variable 
DIET 
(N=5) 
(Mean+S.D.) 
DIET+AT 
(N=6) 
(Mean+S.D) 
DIET+RT 
(N=5) 
(Mean+S.D.) 
Group 
Effect 
Time 
Effect 
Group x Time 
Effect 
Left Ventricle Mass (g) 
0 Weeks 
12 Weeks 
94.5±25.5 
87.3±23.3 
85.9±14.3 
88.1±12.3 
83.9±3.4 
83.7±6.1 
0.784 
 
0.119 
 
0.007 
 
Myocardial Fibrosis 
(%) 
0 Weeks 
12 Weeks 
24.2±1.8 
24.0±0.8 
25.9±1.8 
26.5±1.4 
26.8±1.9 
27.9±1.5 
0.010 
 
0.153 
 
0.348 
 
End Systolic Volume 
(mL) 
0 Weeks 
12 Weeks 
51.9±24.9 
54.3±24.7 
56.1±12.9 
54.0±10.5 
57.9±10.2 
59.3±10.8 
0.866 
 
0.607 
 
0.202 
 
End Diastolic Volume 
(mL) 
0 Weeks 
12 Weeks 
136.9±48.2 
138.4±43.9 
141.4±22.4 
147.0±22.3 
146.1±21.4 
152.9±24.5 
0.836 
 
0.150 
 
0.763 
 
Ejection Fraction (%) 
0 Weeks 
12 Weeks 
63.3±7.9 
61.8±6.7 
60.6±3.9 
63.3±3.6 
60.4±3.4 
61.3±2.4 
0.839 
 
0.433 
 
0.159 
 
 
Table 14: Correlations Between Cardiac MRI Outcomes and baseline Body Weight 
Variable (Baseline Value) LVM (g) Fibrosis (%) EDV (mL) ESV (mL) EF (%) 
Body weight (kg) 0.509* -0.125 0.713** 0.674* -0.276 
Body Mass Index (kg/m2) -0.063 -0.414 0.154 0.251 -0.133 
Waist Circumference (cm) 0.350 -0.015 0.323 0.373 -0.133 
Fat Mass (kg) 0.191 -0.352 0.577* 0.600** -0.356 
Lean Mass (kg) 0.785** 0.026 0.573* 0.585* -0.253 
Body Fat (%) -0.424 -0.484* 0.090 0.129 -0.110 
*Significant correlation at p<0.05 
*Significant correlation at p<0.001 
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Correlational analyses were performed to determine an association between baseline 
measures of body weight and body composition and baseline cardiac MRI outcome variables. 
Baseline body weight and lean mass were correlated to statistically significant higher left 
ventricular mass (p<0.031), end diastolic volume (p<0.013), and end systolic volume (p<0.011). 
Fat mass was correlated to statistically significant greater end diastolic (p=0.012) and end 
systolic (p=0.009) volume. Finally, Body fat percentage was correlated to a statistically 
significant lower percentage of myocardial fibrosis (p=0.042). See Table 14. 
Correlational analyses were also performed to determine an association between the 
change in cardiovascular structure and function and body weight, body mass index, waist 
circumference, fat mass, percent body fat, cardiorespiratory fitness, and muscular strength. 
Correlations are presented in Table 15. Only overall time to reach 85% APMHR was 
significantly correlated to end systolic volume and ejection fraction. No other significant 
correlations were observed. 
  
 84 
Table 15: Correlations Between Cardiac Structure and Function and Primary Outcome Variables 
Variable (Change Score) LVM (g) Fibrosis (%) EDV (mL) ESV (mL) EF (%) 
Body weight (kg) -0.358 0.082 0.043 0.233 -0.093 
Body Mass Index (kg/m2) -0.436 0.053 0.029 0.171 -0.029 
Waist Circumference (cm) -0.200 0.206 0.091 -0.133 0.297 
Fat Mass (kg) 0.028 0.003 0.209 0.037 0.103 
Lean Mass (kg) 0.019 0.441 -0.041 -0.006 0.082 
Body Fat (%) -0.050 -0.229 0.185 0.052 0.079 
GXT Time at 85% APMHR (min) 0.254 -0.053 -0.027 -0.510* 0.565* 
VO2 at 85% APMHR (ml/kg/min) 0.156 -0.091 -0.068 0.029 -0.076 
Leg Press (kg) -0.003 0.196 -0.289 -0.082 -0.178 
Chest Press (kg) -0.107 -0.046 -0.161 0.103 -0.368 
Seated Row (kg) -0.440 -0.205 -0.096 0.083 -0.111 
*Significant correlation at p<0.05 
4.10 PROCESS MEASURES 
Descriptive analyses were conducted to examine: behavioral intervention session attendance, 
exercise session attendance, use of the food diary as represented by reported caloric intake days, 
self-reported calorie intake, and self-reported weight. These data are shown in Table 16. 
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4.10.1 Attendance 
Completers analysis revealed subjects attended nearly 90% (89.3 ± 9.8%) of all behavioral 
intervention sessions. These sessions included individual make-up sessions in addition to the 
regular weekly group meetings. These data were not normally distributed; therefore the Kruskal-
Wallis nonparametric test was used. Attendance was not significantly different between groups 
(DIET: 88.9 ± 4.3%; DIET+AT: 91.7 ± 12.9%; DIET+RT: 87.5 ± 11.5%) (p=0.144).  
4.10.2 Exercise Adherence 
Subjects in the exercise groups attended approximately 85% (84.6 ± 14.2%) of all available 
sessions. Subjects in the DIET+AT (85.7 ± 13.9%) and DIET+RT (83.5 ± 15.8%) groups did not 
significantly differ in total exercise session attendance (p=0.806) at 12 weeks. 
4.10.3 Dietary Self-Monitoring 
Subjects self-reported an average dietary intake of 1344.1 ± 241.0 kilocalories per day in their 
food diary. A one-way ANOVA revealed no significant difference (p=0.542) between the DIET 
(1436.3 ± 313.3kcal), DIET+AT (1306.3 ± 260.9kcal), and DIET+RT (1289.1 ± 125.4kcal) 
groups. The nonparametric Kruskal-Wallis test was performed on the data for the documentation 
of daily caloric intake and self-reported daily weight. There was no significant difference in the 
percentage of days that subjects documented caloric intake (p=0.358) or the number of self-
reported weight days per week (p=0.341). 
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Table 16: 12-Week Process Measure Differences Between Treatment Group 
Outcome Variable 
Total 
(N=6) 
(Mean±S.D.) 
DIET 
(N=6) 
(Mean±S.D.) 
DIET+AT 
(N=6) 
(Mean±S.D) 
DIET+RT 
(N=6) 
(Mean±S.D.) 
Behavioral Intervention 
Session Attendance (%) 89.3 ± 9.8 88.9 ± 4.3 91.7 ± 12.9 87.5 ± 11.5 
Exercise Session 
Attendance (%) 84.6 ± 14.2 ---- 85.7 ± 13.9 83.5 ± 15.8 
Days Diet was Self-
Reported (%) 78.7 ± 23.2 87.3 ± 10.2 81.0 ± 15.3 67.9 ± 35.4 
Self-Reported Calorie 
Intake Per Day 1344.1 ± 241.0 1436.3 ± 313.3 1306.8 ± 260.9 1289.1 ± 125.4 
Self-Reported Weight Days 
Per Week 1.1 ± 2.1 0.5 ± 1.0 0.7 ± 0.8 2.2 ± 3.0 
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5.0  DISCUSSION 
This investigation sought to examine the effect of weight loss induced by diet alone or in 
combination with exercise on body weight, cardiovascular structure and function, muscular 
strength, cardiorespiratory fitness, and body composition in Class II and III Obese women. 
Subjects were randomly assigned to one of three treatment groups: diet only (DIET), diet in 
combination with aerobic exercise (DIET+AT), or diet in combination with resistance exercise 
(DIET+RT). A total of 8 subjects were randomized into each of the three treatment groups. It 
was hypothesized that the DIET+AT group would have the greatest reduction in body weight and 
body composition in addition to the greatest improvement in cardiovascular structure and 
function and cardiorespiratory fitness, whereas the DIET+RT group would have the greatest 
increase in muscular strength. The summary of these findings are outlined below: 
5.1 BODY WEIGHT 
The findings of the current investigation do not support the hypothesis that the DIET+AT group 
would lose significantly more body weight than the DIET+RT group and the DIET+RT group 
would lose more weight than the DIET group. Rather, weight loss at 12 weeks was not 
significantly different between groups (See Table 9). These data are less than those found by 
Ross et al who revealed no significant difference in body weight lost at 12-weeks for males in 
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the diet-induced (-7.8kg) and diet plus exercise-induced (-7.8kg) weight loss groups16. In a 
slightly longer study (16 weeks), Idoate et al showed weight loss for the diet-induced weight loss 
group of -6.4kg and weight loss in the diet plus resistance exercise induced group of -7.7kg99.  
Subjects across all treatment groups lost on average 4.6kg (-4.4%) of baseline body 
weight (p<0.001). The findings support those of Polzien et al who showed a 4.5kg weight loss 
during a 12-week behavioral weight loss intervention in overweight adults who were prescribed 
a reduced calorie diet and exercised 20-40 minutes per day five days per week100.  The overall 
weight loss seen across treatment groups is of clinical importance. A reduction of as little as 5-
10% of baseline body weight has been shown to reduce cardiovascular disease risk21 and was 
nearly attained in the current investigation. This finding suggests that subjects in this intervention 
may have decreased the risk for type 2 diabetes, hypertension, and hyperlipidemia in as little as 
12 weeks. While there was no significant difference between the intervention groups for weight 
loss at 12 weeks (p=0.400), completers in the exercise groups lost approximately 2.5kg more 
body weight than subjects in the diet only group at 12 weeks. While these findings do not 
support the initial hypothesis, a pattern toward greater weight loss is present. Goodpaster et al 
revealed similar findings in six month weight loss of Class II and III obese adults, with an added 
weight loss of 2 – 3kg in exercisers versus non-exercisers39. The additional weight loss observed 
in those assigned to exercise conditions (DIET+AT and DIET+RT) compared to dietary 
restriction alone (DIET) in the current investigation may reflect additional differences in the 
intervention across treatment arms. For example, subjects in DIET+AT and DIET+RT engaged 
in three supervised exercise sessions per week, and this resulted in up to an additional 36 hours 
of contact with the intervention staff (48 hours total) compared to the 12 hours of intervention 
contact time received by DIET.  Perri et al has suggested that added behavioral contact time may 
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be important for increasing weight loss101. It is possible that subjects in DIET+AT and DIET+RT 
received additional information about weight loss or diet behaviors even though instructors for 
the exercise sessions were told to not participate in such discussions. Thus, future studies should 
confirm the differences in weight loss observed in this study with the addition of exercise in a 
design that equates for contact time between participants and intervention staff. 
 Furthermore, the results from the current investigation are consistent with the American 
College of Sports Medicine’s statement that physical activity in bouts of  ≥150 minutes per week  
will result in a 2 – 3kg weight loss68. Thus, while not statistically significant, the weight loss 
results from the current study are consistent with weight loss data in the current literature.  
Across all treatment groups, dietary intake was significantly lower (-639kcal) at week 12 
from baseline (<0.001). In addition, eating behaviors significantly improved (+20.7 on EBI 
scale) from baseline to week 12. Furthermore, total dietary intake from percent fat was 
significantly less at week 12 from baseline (-6.7%) across all groups. These results are slightly 
higher than findings by Jakicic et al who showed a reduction of -498kcal in daily caloric intake 
and percent calories from fat (4.5 %)102. Furthermore, in a six month behavioral weight loss 
intervention, Pellegrini et al found that all subjects increased their eating behavior score by ~14.3 
on the EBI scale103, slightly less than the increase of 20.7 in the current investigation.  
5.2 BODY COMPOSITION AND ANTHROPOMETRIC MEASUREMENTS 
The hypothesis that the DIET+AT group would have a greater improvement in body composition 
than the DIET+RT group and the DIET+RT group would have a greater improvement in body 
composition than the DIET group was not supported by the current findings. Waist and hip 
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circumferences were significantly reduced across all treatment groups from 0 to 12 weeks 
(p<0.001). Subjects in the DIET+RT group had a significantly lower waist circumference (-7.8 ± 
4.0cm) compared to the DIET+AT (-4.9 ± 4.2cm) and DIET (-4.4 ± 6.1cm) groups at 12 weeks. 
Previous research has shown that both aerobic and resistance training are successful in 
decreasing waist circumference104. The results of this investigation are similar to the findings by 
Ross et al that show a significantly greater decrease in waist circumference in the diet and 
resistance training group (-10.0 ± 5.7cm) compared to the diet and aerobic training group (-8.6 ± 
2.8cm) over a 16-week period77. Fat and lean mass were not significantly different between the 
treatment groups but were significantly reduced over 12 weeks in all treatment groups (See Table 
11).  These findings add to those of Geliebter et al that showed a significant decrease in fat mass 
after 8 weeks in the diet (-6.8 ± 2.6kg), diet plus aerobic exercise (-7.2 ± 3.0kg), and diet plus 
resistance exercise (-6.7 ± 2.8kg) groups. Perhaps more importantly, fat free mass was 
significantly reduced at 8 weeks in all treatment groups with subjects in the diet plus resistance 
training group preserving significantly more muscle mass (-1.1 ± 2.3kg lost)105 compared to the 
diet plus aerobic training group (-2.3 ± 2.4kg) and diet only (-2.7 ± 2.1) groups. These results are 
similar to the lean mass lost for the DIET+RT group (-0.9kg) in the current investigation, but not 
the DIET (-1.0kg) or DIET+AT (-0.6kg) groups. The ability of resistance exercise to decrease 
the reduction of lean body mass may not occur in interventions in shorter than 12 weeks in 
duration. 
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5.3 CARDIOVASCULAR STRUCTURE AND FUNCTION 
Severe obesity is associated with abnormalities in cardiac structure and function57. Weight loss, 
especially in individuals with severe obesity, has been shown to significantly improve cardiac 
structure and function106. This investigation was aimed at determining the effect of the addition 
of these two exercise modalities to caloric restriction on changes in left ventricular mass, 
myocardial extravascular extracellular volume fraction (fibrosis score), and volumetric changes 
characterized by end diastolic volume, end systolic volume, and ejection fraction. 
The hypotheses that the DIET+AT group would show a greater improvement in both 
cardiovascular structure and function than the DIET+RT and DIET groups were not supported 
by the findings of this investigation. Subjects in the DIET group had a significantly greater 
reduction in left ventricular mass (-7.2g, p=0.007) than both the DIET+AT (+2.3g) and 
DIET+RT (-0.2g) groups. These findings are similar to other data that suggest a reduction in 
LVM with diet-induced weight loss. Rider et al showed a reduction of LVM of 10g in subjects 
who underwent a low glycemic index diet65. However, these results need to be interpreted with 
caution as weight loss in the cohort was as much as 20kg over a one-year period of time. 
Interestingly, the DIET+AT group showed an increase in LVM in response to aerobic training, 
although not significantly different from baseline. This finding is not consistent with a review 
examining fit adults by Kokkinos et al who suggest that moderate-intensity exercise can improve 
hemodynamics and reduces the amount of work required by the left ventricle, ultimately 
reducing left ventricular mass107. However, a study by Reid et al revealed a non-significant 
increase in left ventricular mass in overweight adults after a 12 week diet (3.0g) and diet plus 
aerobic exercise (3.0g) program at 70% maximal work 90 minutes per week108. It is possible that 
left ventricular mass remained unchanged or elevated due to the intensity of the prescribed 
 92 
exercise in the Reid study and the current investigation. Studies that have shown a successful 
reduction in left ventricular mass with exercise have been at higher intensity and frequency64. 
Highly trained athletes have been shown to have increased LVM, although it is unlikely in this 
population and duration of training that subjects in the DIET+AT group would adapt by 
increasing LVM109.  
While there may not have been a statistically significant change in LVM with exercise, 
there is speculation that the quality of the myocardium may improve with body weight and fat 
mass loss. The measurement of myocardial fibrosis in the context of a weight loss intervention is 
an unexplored area of research. Myocardial fibrosis is the hallmark measure of pathologic 
cardiac remodeling and is characterized by an accumulation of interstitial collagen110. The 
increased collagen interferes with normal electrical signaling and mechanical function of the 
heart. It was hypothesized that a reduction in body weight, specifically fat mass, would result in 
a significant decrease in myocardial fibrosis. The current investigation did not support this 
hypothesis as significant differences were observed between treatment groups at 12 weeks for 
myocardial fibrosis (See Table 13). The measure and analysis of myocardial fibrosis in the 
context of this weight loss intervention were exploratory and inconclusive; however a paradox 
may exist with exercise training, weight loss, and the measurement of fibrosis in this population. 
Subjects in both exercise groups increased myocardial fibrosis percentage from baseline to 12 
weeks (Figure 9) even though both had significant reductions in body weight and fat mass at 12 
weeks from baseline (Figure 5). One possible explanation for this finding may be that the 
measurement of fibrosis in the current investigation did not adjust for capillary beds in the 
myocardium. The contrast dye used in this study is unable to detect these capillaries and 
measurements assume a constant value. While the increase in extracellular space may be due to 
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an increase in collagen fibers, it may be possible that the increase detected by our measurement 
was due to an increase in vascularization with exercise111. If, in the current investigation, 
vascularization within the myocardium increased with exercise, the result would be appropriate 
given the increase in left ventricular mass of the DIET+AT and DIET+RT groups, resulting in 
improvement of the composition of the myocardium as a result of exercise training. Przyklenk 
and Groom showed that after four weeks of voluntary exercise two hours per day six days per 
week, albino rats demonstrated an increase in myocardial revascularization following an 
infarction112. These findings may lend promise to the possibility that the DIET+AT and 
DIET+RT in the current investigation increased fibrosis score at 12 weeks due to an increase in 
capillary density. However, Tharp and Wagner revealed no change in myocardial capillary 
multiplication in albino rats that underwent a training regimen varying from 90 to 300 minutes 
per week, suggesting that improvements in myocardial blood flow due to exercise may be a 
result of an increase in the size of the coronary arteries or improved collateral circulation113. 
Thus, the effect of weight loss and exercise on myocardial fibrosis needs to be explored further 
and future investigations should incorporate the appropriate intravenous dye to measure capillary 
density change within the left ventricle in response to diet, exercise, and weight loss.  
The volumetric data also does not support the hypothesis that the DIET+AT group would 
have a significantly greater improvement in cardiovascular function compared to the DIET+RT 
and DIET groups. End diastolic volumes increased for all treatment groups from baseline to 12 
weeks, however the findings were not statistically significant (p=0.150). End systolic volumes 
increased for the DIET and DIET+RT groups, whereas it decreased in the DIET+AT group. 
Karnassis et al reveal opposite findings in volumetric data in relation to decreased body weight. 
Long term follow-up of bariatric surgery patients revealed significantly lower end diastolic 
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volume in patients that maintained a BMI of less than 32kg/m2 (87.0±12.2mL) compared to 
those with a BMI greater than 42kg/m2 (113.0±23.8)114. However, Dehmer et al show an acute 
increase in end diastolic volume during supine exercise of approximately 25mL115. Furthermore, 
four weeks of exercise training has been shown to increase left ventricular diastolic diameter 
from 4.98 to 5.11cm116. An increase in end diastolic volume associated with exercise training 
seen in the current investigation may suggest that exercise training was sufficient to maintain left 
ventricular end diastolic volume that has been shown to decrease with weight loss. 
5.4 CARDIORESPIRATORY FITNESS 
There was no significant time or group effect for change in VO2 at 85% of APMHR. However, 
when examining the change scores the DIET+AT group increased their treadmill time by 1.9 
minutes, whereas the DIET+RT and DIET groups increased their time each by 0.8 minutes. 
These findings partially support the hypothesis that the DIET+AT group would have a 
significantly greater improvement in cardiorespiratory fitness than the DIET+RT and DIET 
groups, though not statistically significant. The lack of statistically significant findings is 
supported by Mendonca et al who suggest over 12 weeks the addition of resistance training two 
days per week to an aerobic training regimen is not sufficient to significantly improve 
submaximal VO2 compared to aerobic exercise alone117. 
Further examination of the data reveal that the DIET and DIET+AT groups showed a 
slight decrease in absolute VO2 at 12 weeks. These results are not consistent with the current 
literature by Church et al that shows an improvement in VO2 Peak over six months in all three 
different aerobic exercise training groups118. Thus, these findings in combination with a greater 
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increase in time to reach 85% APMHR across groups may suggest an alternative adaptation to 
aerobic training seen in this population. One possible explanation may be that subjects in all 
groups lost significant weight from baseline. Reduction in body weight, specifically adipose 
tissue, would require a lesser metabolic cost of activity at a given intensity. Subjects may have 
been able to achieve a greater treadmill time from baseline simply because they became more 
mechanically efficient as they increased work without a subsequent increase in VO2 during 
submaximal exercise. Finally, there may be central and/or peripheral responses to exercise that 
occur short-term that allowed the subjects to increase treadmill time from baseline. As little as 16 
weeks of submaximal aerobic training has been shown to improve ateriovenous oxygen 
difference in healthy, young adults119, resulting in greater improvements in maximal oxygen 
uptake. The current investigation did not measure central or peripheral adaptations to exercise 
and only 85% APMHR VO2 was obtained. The possible explanations given for an increase in 
treadmill time are speculative and future research should focus on determining a treatment effect 
of exercise training on submaximal oxygen consumption in this population. 
An increase from baseline to 12 weeks in self-reported physical activity was observed for 
completers (377.6 ± 744.7kcal) and in the intent-to-treat analysis (283.2 ± 661.7kcal), possibly 
adding to the finding of non-significant group differences at 12 weeks. While it was expected 
that the DIET+AT and DIET+RT groups would see a significantly higher increase in kilocalorie 
expenditure per week, these groups were not significantly different from the DIET group at week 
12 (p=0.506). A closer examination of mean kilocalorie expenditure does show that the 
DIET+AT group (approximately 454kcal) and the DIET+RT group (approximately 506kcal) had 
greater caloric expenditure than the DIET group (approximately 172kcal) per week. These 
changes are less than Jeffery observed at six months for dieters (+551kcal/week) and high 
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volume exercisers (+1121kcal/week)70. The mean caloric expenditure may not be significantly 
different between groups due to an increase in physical activity by the DIET group outside of the 
intervention. At the beginning of the study, subjects in each group were asked to not engage in a 
structured exercise plan for the duration of the intervention. However, they were told that they 
should maintain their normal activities of daily living yet they increased their caloric expenditure 
(+172kcal/wk). Future studies should focus on controlling physical activity outside of supervised 
exercise sessions to better determine the effect of exercise on the outcome variables. 
5.5 MUSCULAR STRENGTH 
Subjects in all three treatment groups showed significant improvements in upper body strength 
measures from baseline to 12 weeks (p<0.001). There was a trend toward increase in lower body 
strength (p=0.098) measured by the leg press but no significant differences in any maximal 
strength measure between groups (p>0.189). These findings do not support the hypothesis that 
the DIET+RT group would have a greater increase in muscular strength compared to the 
DIET+AT and DIET groups. However, while not significant, the DIET+RT group did have a 
greater change score for all three strength measures compared to the other two groups (See Table 
9 and Figure 7). These trends in maximal strength change scores are similar to those found by 
Donges et al who show a greater increase in lower and upper body strength in resistance trained 
subjects (+45kg and +17kg, respectively) compared to aerobic trained (+19kg and +2.8kg, 
respectively) subjects and controls (+2.7kg and +0.6kg, respectively) during a 10-week training 
protocol120. The short duration of this intervention, in addition to the gradual increase of stimulus 
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(Tables 4 and 5), may have caused a non-significant difference between treatment groups for 
maximal weight lifted. 
5.6 LIMITATIONS AND FUTURE DIRECTIONS 
This investigation examined the effects of diet alone or in combination with exercise on changes 
in cardiovascular structure and function in Class II and III obese adults and thus served as a pilot 
investigation. There are several factors that may have impacted the main outcomes and the 
results should be interpreted accordingly. Future studies should consider the following: 
1. This investigation included a small sample size that was likely not large enough to elicit 
between group differences in body weight, cardiovascular measures, body composition, 
physical activity and dietary intake. However, the current study provides effect size to 
adequately power a future study. Future studies should employ a similar intervention to a 
larger sample of subjects. 
2. This investigation was 12 weeks in duration which may not have been enough time to 
provide sufficient stimulus to detect significant differences between the treatment groups. 
Future studies should examine the main outcome variables over a longer period of time. 
3. This investigation included females only; therefore the findings cannot be generalized to 
men as well. Therefore, future studies should include males to determine gender 
differences in the outcome variables. 
4. The stimulus provided by the aerobic training protocol may not have been aggressive 
enough to elicit an expected response from the outcomes. For example, there was a five 
week period over which intensity increased to the prescribed 180 minutes per week, 
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which may not have been enough time at the prescribed dose of aerobic exercise. Future 
studies should consider a greater volume of aerobic exercise for the given time period to 
detect greater differences in the outcome variables. 
5. Subjects in the DIET+RT group may not have been exposed to a sufficient resistance 
stimulus to result in significant differences in strength measures between treatment 
groups. Future studies should consider a more aggressive resistance exercise protocol, 
such as the protocol used by Donnelly121, to provide sufficient stimulus to maximize 
strength gains. The exercises involving Thera-bands and resistance tubing may not have 
elicited a large enough stimulus to result in a significantly greater improvement in 
strength in the DIET+RT group. 
6. Weight loss in the DIET+AT and DIET+RT treatment groups were greater than in the 
DIET group, although not statistically significant. The exercising groups were required to 
attend three supervised exercise sessions per week in addition to the weekly group 
meeting. It is possible that the additional contact may have positively influenced weight 
loss behaviors in the DIET+AT and DIET+RT groups. Future investigations may need an 
additional contact (in person or telephone) per week to the DIET group to increase 
contact and standardize with the exercise groups. 
7. This investigation did not include the measure of traditional cardiovascular disease risk 
factors such as total cholesterol and blood lipids. Future investigations should include 
these markers to determine cardiovascular disease risk pre and post weight loss induced 
by diet or diet in addition to aerobic or resistance exercise in Class II and III obese adults. 
8. This investigation employed a submaximal exercise test to determine cardiorespiratory 
fitness. It is possible that the statistically significant changes not seen in VO2 at 85% 
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APMHR between the treatment groups may be observed at maximal effort. Future 
investigations should utilize a maximal treadmill test to examine differences in maximal 
oxygen uptake between treatment groups. 
9. Visceral adiposity has been shown to be associated with increased risk for cardiovascular 
disease8. However, this measurement was not attained for the current investigation. 
Future studies should include CT scan or MRI to appropriately determine this measure of 
adiposity and examine its association with weight loss and exercise training in this 
population. 
10. The outcome variables obtained from the cardiac MRI (left ventricular mass, fibrosis, end 
diastolic volume, end systolic volume, and ejection fraction) were taken at rest and 
therefore may not reflect responses to exercise. Future investigations should incorporate 
techniques to measure these variables, especially end diastolic volume, end systolic 
volume, and ejection fraction after an acute bout of exercise (physical stressor) to 
examine exercise-induced changes in these variables. 
11. The subjects in this investigation had a mean age of 45.4 years and ranged from 32 to 55 
years. These results can not be generalized to individuals of younger or older age 
demographic. Therefore, future investigations should seek to understand the effect of 
weight loss and exercise on left ventricular mass, fibrosis, end diastolic volume, end 
systolic volume, and ejection fraction on populations such as adolescents and the elderly.  
12. Subjects were prescreened for use of medications that influence blood pressure and heart 
rate response. However, no further screening of medication use was conducted. 
Therefore, future investigations should perform more detailed screening into medication 
use to examine their possible effect on these cardiovascular outcome variables.  
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5.7 CONCLUSION 
In conclusion, the current investigation was successful in producing weight loss, increasing 
muscular strength, and improving body composition and dietary habits. Several important 
conclusions can be drawn from this study even though cardiovascular structure and function 
outcomes showed little significant difference between treatment groups.  
 First, an intervention including behavioral, diet, and exercise therapy can be successfully 
implemented in Class II and III obese women. Second, quantifiable changes were seen in 
cardiovascular structure and function outcomes. Left ventricular hypertrophy is associated with 
poor health outcomes. In this investigation, exercise appeared to counteract the effect of weight 
loss on LVM reduction. However, it appears that cardiac structure and function can improve in 
Class II and III obese women in response to exercise training and modest weight loss. The 
elevated end diastolic volumes in the DIET+AT and DIET+RT groups may reflect an acute 
effect of exercise on this measure and not chronic adaptations seen with exercise training. Lastly, 
this study showed that cardiac MRI is a feasible technique to measure and detect positive 
changes in left ventricular structural and functional changes in Class II and III obese women.  
 The findings are promising and may require longer duration and an increased sample size to 
find clinical significance. This investigation served as a pilot study and thus, additional studies 
should be conducted to replicate and improve upon the findings of this study. Future studies 
should include a longer duration and increased sample size to be better able to detect between 
group differences. In addition, future studies should incorporate a more aggressive training 
protocol for both aerobic and resistance exercise to better determine the effect of exercise on 
changes in cardiovascular structure and function in this population. 
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APPENDIX A 
CARDIAC MRI OUTCOME VARIABLES – ABSOLUTE VALUES 
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*Subjects 18 and 23 did not complete 12 Week Cardiac MRI. Baseline data not shown. 
 
  
 Outcome Variable 
 Left Ventricular Mass 
(g) 
Myocardial Fibrosis 
(%) 
End Diastolic 
Volume (mL) 
End Systolic 
Volume (mL) 
Ejection Fraction (%) 
Subject Baseline Week 12 Baseline Week 12 Baseline Week 12 Baseline Week 12 Baseline Week 12 
1 93.3 89.1 28.3 28.4 165.8 178.4 70.0 69.4 57.7 61.1 
3 84.2 86.6 24.8 26.7 161.4 178.9 72.0 74.4 55.4 58.4 
4 82.6 77.1 28.1 29.7 172.7 169.1 62.8 65.0 63.6 61.5 
5 123.6 112.6 22.9 23.5 170 185.2 84.8 90.6 50.1 51.0 
6 113.5 108.6 25.9 25.1 197.5 178 66.7 67.1 66.2 62.3 
7 87.8 91.0 24.8 27.5 138 159.9 50.8 56.1 63.1 64.9 
8 86.0 86.0 29.0 29.3 118.1 118.1 45.9 45.9 61.1 61.1 
9 65.8 69.7 24.2 26.4 106.6 123.3 41.2 44.2 61.3 64.1 
10 103.7 101.7 23.4 24.6 151 147.2 66.1 57.1 56.2 61.2 
11 77.2 85.9 26.6 27.4 160.8 167.5 66.6 61.4 58.5 63.3 
14 61.9 60.2 24.3 23.1 84.3 85.5 25.7 33.2 69.5 61.1 
15 96.8 101.5 26.0 25.3 126.9 140.4 42.5 42.1 66.5 70.0 
17 78.4 80.8 26.6 26.5 137.5 125.2 50.4 50.0 63.3 60.1 
21 96.6 86.1 25.8 23.9 137.6 138.7 52.3 47.7 61.9 65.6 
24 76.7 69.0 21.7 24.2 95.1 104.4 29.8 32.7 68.6 68.6 
25 78.9 77.6 26.8 26.2 140.1 138.7 58.2 55.0 58.4 60.3 
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APPENDIX B 
INDIVIDUAL LEFT VENTRICULAR MASS CHANGE SCORES 
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APPENDIX C 
INDIVIDUAL MYOCARDIAL FIBROSIS (Ve) CHANGE SCORES 
  
 106 
 
 
 
 
-3
-2
-1
0
1
2
3
Pe
rc
en
t (
%
)
Ve Change - DIET
-1
-0.5
0
0.5
1
1.5
2
2.5
Pe
rc
en
t (
%
)
Ve Change – DIET+AT
-1
-0.5
0
0.5
1
1.5
2
2.5
3
Pe
rc
en
t (
%
)
Ve Change – DIET+RT
 107 
APPENDIX D 
INDIVIDUAL END DIASTOLIC VOLUME CHANGE SCORES 
  
 108 
 
 
 
  
-25
-20
-15
-10
-5
0
5
10
15
20
Vo
lu
m
e 
(m
L
)
EDV Change - DIET
-15
-10
-5
0
5
10
15
20
Vo
lu
m
e 
(m
L
)
EDV Change – DIET+AT
-5
0
5
10
15
20
25
Vo
lu
m
e 
(m
L
)
EDV Change – DIET+RT
 109 
APPENDIX E 
INDIVIDUAL END SYSTOLIC VOLUME CHANGE SCORES 
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APPENDIX F 
INDIVIDUAL EJECTION FRACTION CHANGE SCORES 
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